{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:47:02Z","timestamp":1792608422788,"version":"4.5.0"},"reference-count":573,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09119-1","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:11:44Z","timestamp":1767010304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunopathogenesis and Therapeutics of Systemic Lupus Erythematosus: an Integrative Review"],"prefix":"10.1007","volume":"68","author":[{"given":"Qian","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"9119_CR1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fimmu.2019.00772","volume":"10","author":"AA Herrada","year":"2019","unstructured":"Herrada AA et al (2019) Innate immune cells\u2019 contribution to systemic lupus erythematosus. Front Immunol 10:772","journal-title":"Front Immunol"},{"issue":"9","key":"9119_CR2","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M et al (2019) 2019 European league against Rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71(9):1400\u20131412","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"9119_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","volume":"10","author":"X Dai","year":"2025","unstructured":"Dai X, Fan Y, Zhao X (2025) Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics. Signal Transduct Target Therapy 10(1):102","journal-title":"Signal Transduct Target Therapy"},{"issue":"25","key":"9119_CR4","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1056\/NEJMoa035471","volume":"349","author":"MJ Roman","year":"2003","unstructured":"Roman MJ et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399\u20132406","journal-title":"N Engl J Med"},{"key":"9119_CR5","doi-asserted-by":"crossref","unstructured":"Bolouri N et al (2022) Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus. Inflamm Res 71(5):537\u2013554","DOI":"10.1007\/s00011-022-01554-6"},{"key":"9119_CR6","doi-asserted-by":"crossref","unstructured":"Jung L, Paul WM (2021) Autoimmune disorders. Biochemical and molecular basis of pediatric disease. Elsevier, pp 777\u2013826","DOI":"10.1016\/B978-0-12-817962-8.00019-6"},{"issue":"8","key":"9119_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","volume":"82","author":"MK Crow","year":"2023","unstructured":"Crow MK (2023) Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis 82(8):999\u20131014","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"9119_CR8","doi-asserted-by":"publisher","first-page":"7666","DOI":"10.3390\/ijms25147666","volume":"25","author":"F Yasmeen","year":"2024","unstructured":"Yasmeen F et al (2024) Understanding autoimmunity: mechanisms, predisposing factors, and cytokine therapies. Int J Mol Sci 25(14):7666","journal-title":"Int J Mol Sci"},{"issue":"12","key":"9119_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos GC et al (2016) New insights into the Immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12(12):716\u2013730","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"9119_CR10","first-page":"575","volume":"18","author":"A Psarras","year":"2022","unstructured":"Psarras A, Wittmann M, Vital EM (2022) Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol 18(10):575\u2013590","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"9119_CR11","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","volume":"192","author":"MK Crow","year":"2014","unstructured":"Crow MK (2014) Type I interferon in the pathogenesis of lupus. J Immunol 192(12):5459\u20135468","journal-title":"J Immunol"},{"issue":"10188","key":"9119_CR12","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","volume":"393","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner T, Furie R (2019) Novel paradigms in systemic lupus erythematosus. Lancet 393(10188):2344\u20132358","journal-title":"Lancet"},{"key":"9119_CR13","doi-asserted-by":"crossref","unstructured":"Moutsopoulos HM et al (2018) Autoimmune Rheumatic Disorders: Pathogenetic and Laboratory Aspects. Rheumatology in Questions, : pp. 21\u201336","DOI":"10.1007\/978-3-319-71604-6_2"},{"issue":"9","key":"9119_CR14","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1001\/jamainternmed.2015.3528","volume":"175","author":"C-F Kuo","year":"2015","unstructured":"Kuo C-F et al (2015) Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med 175(9):1518\u20131526","journal-title":"JAMA Intern Med"},{"key":"9119_CR15","unstructured":"Juli\u00e0 A et al (2018) Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus, vol 20. Arthritis research & therapy, pp 1\u201310"},{"issue":"1","key":"9119_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s10020-018-0019-4","volume":"24","author":"J Bhattacharya","year":"2018","unstructured":"Bhattacharya J et al (2018) Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. Mol Med 24(1):24","journal-title":"Mol Med"},{"key":"9119_CR17","doi-asserted-by":"publisher","first-page":"1398035","DOI":"10.3389\/flupu.2024.1398035","volume":"2","author":"V Laurynenka","year":"2024","unstructured":"Laurynenka V, Harley JB (2024) The 330 risk loci known for systemic lupus erythematosus (SLE): a review. Front Lupus 2:1398035","journal-title":"Front Lupus"},{"issue":"10","key":"9119_CR18","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1080\/1744666X.2023.2240959","volume":"19","author":"S Guga","year":"2023","unstructured":"Guga S et al (2023) A review of genetic risk in systemic lupus erythematosus. Expert Rev Clin Immunol 19(10):1247\u20131258","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"9119_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-genom-091212-153455","volume":"14","author":"J Trowsdale","year":"2013","unstructured":"Trowsdale J, Knight JC (2013) Major histocompatibility complex genomics and human disease. Annu Rev Genom Hum Genet 14(1):301\u2013323","journal-title":"Annu Rev Genom Hum Genet"},{"issue":"1","key":"9119_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0090-1229(91)90111-M","volume":"60","author":"A Kumar","year":"1991","unstructured":"Kumar A, Kumar P, Schur PH (1991) DR3 and nonDR3 associated complement component C4A deficiency in systemic lupus erythematosus. Clin Immunol Immunopathol 60(1):55\u201364","journal-title":"Clin Immunol Immunopathol"},{"issue":"7813","key":"9119_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41586-020-2277-x","volume":"582","author":"N Kamitaki","year":"2020","unstructured":"Kamitaki N et al (2020) Complement genes contribute sex-biased vulnerability in diverse disorders. Nature 582(7813):577\u2013581","journal-title":"Nature"},{"issue":"1","key":"9119_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13075-016-1117-8","volume":"18","author":"F Panza","year":"2016","unstructured":"Panza F et al (2016) A novel DNA\/histone H4 peptide complex detects autoantibodies in systemic lupus erythematosus Sera. Arthritis Res Therapy 18(1):220","journal-title":"Arthritis Res Therapy"},{"issue":"4","key":"9119_CR23","doi-asserted-by":"publisher","first-page":"e1008092","DOI":"10.1371\/journal.pgen.1008092","volume":"15","author":"JE Molineros","year":"2019","unstructured":"Molineros JE et al (2019) Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians. PLoS Genet 15(4):e1008092","journal-title":"PLoS Genet"},{"issue":"21","key":"9119_CR24","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1093\/hmg\/ddy280","volume":"27","author":"KB Hanscombe","year":"2018","unstructured":"Hanscombe KB et al (2018) Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet 27(21):3813\u20133824","journal-title":"Hum Mol Genet"},{"key":"9119_CR25","doi-asserted-by":"publisher","first-page":"e12089","DOI":"10.7554\/eLife.12089","volume":"5","author":"P Raj","year":"2016","unstructured":"Raj P et al (2016) Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity. Elife 5:e12089","journal-title":"Elife"},{"issue":"1","key":"9119_CR26","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1038\/ncomms6902","volume":"5","author":"K Kim","year":"2014","unstructured":"Kim K et al (2014) The HLA-DR\u03b21 amino acid positions 11-13-26 explain the majority of SLE\u2013MHC associations. Nat Commun 5(1):5902","journal-title":"Nat Commun"},{"issue":"2","key":"9119_CR27","doi-asserted-by":"publisher","first-page":"e20190668","DOI":"10.1084\/jem.20190668","volume":"217","author":"P Majumder","year":"2019","unstructured":"Majumder P et al (2019) A super enhancer controls expression and chromatin architecture within the MHC class II locus. J Exp Med 217(2):e20190668","journal-title":"J Exp Med"},{"issue":"10","key":"9119_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41584-024-01152-2","volume":"20","author":"Y Ghodke-Puranik","year":"2024","unstructured":"Ghodke-Puranik Y, Olferiev M, Crow MK (2024) Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy. Nat Rev Rheumatol 20(10):635\u2013648","journal-title":"Nat Rev Rheumatol"},{"key":"9119_CR29","doi-asserted-by":"crossref","unstructured":"Shiina T, Kulski JK (2024) HLA genetics for the human diseases. Basic Immunol its Clin Application, : p. 237\u2013258","DOI":"10.1007\/978-981-99-9781-7_16"},{"issue":"5","key":"9119_CR30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ajhg.2012.08.026","volume":"91","author":"DL Morris","year":"2012","unstructured":"Morris DL et al (2012) Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans. Am J Hum Genet 91(5):778\u2013793","journal-title":"Am J Hum Genet"},{"key":"9119_CR31","doi-asserted-by":"crossref","unstructured":"Graham RR et al (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proceedings of the National Academy of Sciences, 104(16): pp. 6758\u20136763","DOI":"10.1073\/pnas.0701266104"},{"issue":"12","key":"9119_CR32","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","volume":"20","author":"FJ Barrat","year":"2019","unstructured":"Barrat FJ, Crow MK, Ivashkiv LB (2019) Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol 20(12):1574\u20131583","journal-title":"Nat Immunol"},{"key":"9119_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3389\/fimmu.2019.00325","volume":"10","author":"CA Jefferies","year":"2019","unstructured":"Jefferies CA (2019) Regulating IRFs in IFN driven disease. Front Immunol 10:325","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR34","doi-asserted-by":"publisher","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","volume":"6","author":"L R\u00f6nnblom","year":"2019","unstructured":"R\u00f6nnblom L, Leonard D (2019) Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 6(1):e000270","journal-title":"Lupus Sci Med"},{"issue":"5","key":"9119_CR35","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/art.21031","volume":"52","author":"KA Kirou","year":"2005","unstructured":"Kirou KA et al (2005) Activation of the interferon-\u03b1 pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthr Rhuem 52(5):1491\u20131503","journal-title":"Arthr Rhuem"},{"key":"9119_CR36","doi-asserted-by":"publisher","first-page":"155633","DOI":"10.1016\/j.cyto.2021.155633","volume":"146","author":"S Gallucci","year":"2021","unstructured":"Gallucci S, Meka S, Gamero AM (2021) Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. Cytokine 146:155633","journal-title":"Cytokine"},{"key":"9119_CR37","doi-asserted-by":"crossref","unstructured":"Miyachi K et al (2023) Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis, vol 25. Arthritis Research & Therapy, p 26. 1","DOI":"10.1186\/s13075-023-03010-0"},{"key":"9119_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","volume":"67","author":"M Postal","year":"2020","unstructured":"Postal M et al (2020) Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol 67:87\u201394","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"9119_CR39","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa073003","volume":"357","author":"EF Remmers","year":"2007","unstructured":"Remmers EF et al (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357(10):977\u2013986","journal-title":"N Engl J Med"},{"issue":"5","key":"9119_CR40","doi-asserted-by":"publisher","first-page":"e1000084","DOI":"10.1371\/journal.pgen.1000084","volume":"4","author":"KE Taylor","year":"2008","unstructured":"Taylor KE et al (2008) Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 4(5):e1000084","journal-title":"PLoS Genet"},{"issue":"7","key":"9119_CR41","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2017-212794","volume":"77","author":"N Hagberg","year":"2018","unstructured":"Hagberg N et al (2018) The STAT4 SLE risk allele rs7574865 [T] is associated with increased IL-12-induced IFN-\u03b3 production in T cells from patients with SLE. Ann Rheum Dis 77(7):1070\u20131077","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"9119_CR42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1172\/JCI118855","volume":"98","author":"M Koshy","year":"1996","unstructured":"Koshy M, Berger D, Crow MK (1996) Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98(3):826\u2013837","journal-title":"J Clin Invest"},{"issue":"9","key":"9119_CR43","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJMoa0707865","volume":"358","author":"G Hom","year":"2008","unstructured":"Hom G et al (2008) Association of systemic lupus erythematosus with C8orf13\u2013BLK and ITGAM\u2013ITGAX. N Engl J Med 358(9):900\u2013909","journal-title":"N Engl J Med"},{"issue":"2","key":"9119_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/ng.79","volume":"40","author":"SV Kozyrev","year":"2008","unstructured":"Kozyrev SV et al (2008) Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 40(2):211\u2013216","journal-title":"Nat Genet"},{"issue":"9","key":"9119_CR45","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/ng.202","volume":"40","author":"SL Musone","year":"2008","unstructured":"Musone SL et al (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40(9):1062\u20131064","journal-title":"Nat Genet"},{"issue":"3","key":"9119_CR46","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/art.30188","volume":"63","author":"K Hikami","year":"2011","unstructured":"Hikami K et al (2011) Association of a functional polymorphism in the 3\u2032-untranslated region of SPI1 with systemic lupus erythematosus. Arthr Rhuem 63(3):755\u2013763","journal-title":"Arthr Rhuem"},{"issue":"11","key":"9119_CR47","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.2439","volume":"44","author":"N Manjarrez-Ordu\u00f1o","year":"2012","unstructured":"Manjarrez-Ordu\u00f1o N et al (2012) CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat Genet 44(11):1227\u20131230","journal-title":"Nat Genet"},{"issue":"10","key":"9119_CR48","doi-asserted-by":"publisher","first-page":"bqab152","DOI":"10.1210\/endocr\/bqab152","volume":"162","author":"BF Brian 4th","year":"2021","unstructured":"Brian BF 4th, Freedman TS (2021) The Src-family kinase Lyn in immunoreceptor signaling. Endocrinology 162(10):bqab152","journal-title":"Endocrinology"},{"key":"9119_CR49","doi-asserted-by":"crossref","unstructured":"Tizaoui K et al (2021) The role of PTPN22 in the pathogenesis of autoimmune diseases: A comprehensive review. Seminars in arthritis and rheumatism. Elsevier","DOI":"10.1016\/j.semarthrit.2021.03.004"},{"issue":"2","key":"9119_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/35100573","volume":"1","author":"MJ Shlomchik","year":"2001","unstructured":"Shlomchik MJ, Craft JE, Mamula MJ (2001) From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 1(2):147\u2013153","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"9119_CR51","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","volume":"41","author":"S Caielli","year":"2023","unstructured":"Caielli S, Wan Z, Pascual V (2023) Systemic lupus erythematosus pathogenesis: interferon and beyond. Annu Rev Immunol 41(1):533\u2013560","journal-title":"Annu Rev Immunol"},{"key":"9119_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fimmu.2016.00035","volume":"7","author":"A Mahajan","year":"2016","unstructured":"Mahajan A, Herrmann M, Mu\u00f1oz LE (2016) Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol 7:35","journal-title":"Front Immunol"},{"key":"9119_CR53","doi-asserted-by":"crossref","unstructured":"Schulz K, Trendelenburg M (2022) C1q as a target molecule to treat human disease: What do mouse studies teach us? Front Immunol 13:958273","DOI":"10.3389\/fimmu.2022.958273"},{"issue":"1","key":"9119_CR54","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.immunol.22.012703.104549","volume":"22","author":"AP Manderson","year":"2004","unstructured":"Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22(1):431\u2013456","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"9119_CR55","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1586\/1744666X.4.5.629","volume":"4","author":"M Kallel-Sellami","year":"2008","unstructured":"Kallel-Sellami M et al (2008) Complement deficiency and systemic lupus erythematosus: consensus and dilemma. Expert Rev Clin Immunol 4(5):629\u2013637","journal-title":"Expert Rev Clin Immunol"},{"key":"9119_CR56","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coi.2017.10.008","volume":"49","author":"P Costa-Reis","year":"2017","unstructured":"Costa-Reis P, Sullivan KE (2017) Monogenic lupus: it\u2019s all new! Curr Opin Immunol 49:87\u201395","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"9119_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0961203309346508","volume":"19","author":"R Aggarwal","year":"2010","unstructured":"Aggarwal R et al (2010) Complete complement deficiency in a large cohort of Familial systemic lupus erythematosus. Lupus 19(1):52\u201357","journal-title":"Lupus"},{"issue":"1","key":"9119_CR58","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ng0598-56","volume":"19","author":"M Botto","year":"1998","unstructured":"Botto M et al (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19(1):56\u201359","journal-title":"Nat Genet"},{"issue":"5","key":"9119_CR59","doi-asserted-by":"publisher","first-page":"e20201138","DOI":"10.1084\/jem.20201138","volume":"218","author":"J Hartl","year":"2021","unstructured":"Hartl J et al (2021) Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. J Exp Med 218(5):e20201138","journal-title":"J Exp Med"},{"issue":"1","key":"9119_CR60","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41467-023-37083-x","volume":"14","author":"E Gomez-Ba\u00f1uelos","year":"2023","unstructured":"Gomez-Ba\u00f1uelos E et al (2023) Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and DsDNA in systemic lupus erythematosus. Nat Commun 14(1):1388","journal-title":"Nat Commun"},{"issue":"5","key":"9119_CR61","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1084\/jem.20042251","volume":"201","author":"S Yurasov","year":"2005","unstructured":"Yurasov S et al (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201(5):703\u2013711","journal-title":"J Exp Med"},{"issue":"6","key":"9119_CR62","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.coi.2008.09.001","volume":"20","author":"E Meffre","year":"2008","unstructured":"Meffre E, Wardemann H (2008) B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 20(6):632\u2013638","journal-title":"Curr Opin Immunol"},{"issue":"6388","key":"9119_CR63","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aao4555","volume":"360","author":"GS Ling","year":"2018","unstructured":"Ling GS et al (2018) C1q restrains autoimmunity and viral infection by regulating CD8\u2009+\u2009T cell metabolism. Science 360(6388):558\u2013563","journal-title":"Science"},{"key":"9119_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","volume":"7","author":"ACL Macedo","year":"2016","unstructured":"Macedo ACL, Isaac L (2016) Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol 7:55","journal-title":"Front Immunol"},{"key":"9119_CR65","doi-asserted-by":"crossref","unstructured":"Wang H et al (2022) Risk of C1q variation in systemic lupus erythematosus: a meta-analysis with trial sequential Analysis. Advances in dermatology and Allergology\/Post\u0119py dermatologii i alergologii. 39(2):353\u2013361","DOI":"10.5114\/ada.2022.115965"},{"issue":"1","key":"9119_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1017\/S0954422421000287","volume":"36","author":"T Montoya","year":"2023","unstructured":"Montoya T et al (2023) Epigenetic linkage of systemic lupus erythematosus and nutrition. Nutr Res Rev 36(1):39\u201359","journal-title":"Nutr Res Rev"},{"issue":"3\u20134","key":"9119_CR67","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jaut.2009.03.011","volume":"33","author":"J Zhang","year":"2009","unstructured":"Zhang J et al (2009) Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential. J Autoimmun 33(3\u20134):270\u2013274","journal-title":"J Autoimmun"},{"issue":"5","key":"9119_CR68","doi-asserted-by":"publisher","first-page":"11013","DOI":"10.3390\/ijms160511013","volume":"16","author":"H Wu","year":"2015","unstructured":"Wu H et al (2015) The real culprit in systemic lupus erythematosus: abnormal epigenetic regulation. Int J Mol Sci 16(5):11013\u201311033","journal-title":"Int J Mol Sci"},{"issue":"8","key":"9119_CR69","doi-asserted-by":"publisher","first-page":"e1003678","DOI":"10.1371\/journal.pgen.1003678","volume":"9","author":"DM Absher","year":"2013","unstructured":"Absher DM et al (2013) Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4\u2009+\u2009T-cell populations. PLoS Genet 9(8):e1003678","journal-title":"PLoS Genet"},{"key":"9119_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1050-x","volume":"18","author":"H Zhu","year":"2016","unstructured":"Zhu H et al (2016) Whole-genome transcription and DNA methylation analysis of peripheral blood mononuclear cells identified aberrant gene regulation pathways in systemic lupus erythematosus. Arthritis Res Therapy 18:1\u201317","journal-title":"Arthritis Res Therapy"},{"key":"9119_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jaut.2015.06.004","volume":"62","author":"FM Strickland","year":"2015","unstructured":"Strickland FM et al (2015) CD4\u2009+\u2009T cells epigenetically modified by oxidative stress cause lupus-like autoimmunity in mice. J Autoimmun 62:75\u201380","journal-title":"J Autoimmun"},{"issue":"6","key":"9119_CR72","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/cmi.2017.137","volume":"15","author":"P Zhang","year":"2018","unstructured":"Zhang P, Lu Q (2018) Genetic and epigenetic influences on the loss of tolerance in autoimmunity. Cell Mol Immunol 15(6):575\u2013585","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"9119_CR73","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2217\/epi-2016-0096","volume":"9","author":"CM Hedrich","year":"2017","unstructured":"Hedrich CM et al (2017) DNA methylation in systemic lupus erythematosus. Epigenomics 9(4):505\u2013525","journal-title":"Epigenomics"},{"issue":"11","key":"9119_CR74","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1136\/annrheumdis-2015-208410","volume":"75","author":"M Zhao","year":"2016","unstructured":"Zhao M et al (2016) IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus. Ann Rheum Dis 75(11):1998\u20132006","journal-title":"Ann Rheum Dis"},{"key":"9119_CR75","doi-asserted-by":"crossref","unstructured":"Mai L et al (2021) The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus, vol 23. Arthritis research & therapy, p 29. 1","DOI":"10.1186\/s13075-021-02414-0"},{"key":"9119_CR76","doi-asserted-by":"publisher","first-page":"108612","DOI":"10.1016\/j.clim.2020.108612","volume":"221","author":"B Zhang","year":"2020","unstructured":"Zhang B et al (2020) A simple and highly efficient method of IFI44L methylation detection for the diagnosis of systemic lupus erythematosus. Clin Immunol 221:108612","journal-title":"Clin Immunol"},{"issue":"2","key":"9119_CR77","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41390-024-03135-1","volume":"96","author":"J Wang","year":"2024","unstructured":"Wang J et al (2024) DNA methylation of IFI44L as a potential blood biomarker for childhood-onset systemic lupus erythematosus. Pediatr Res 96(2):494\u2013501","journal-title":"Pediatr Res"},{"issue":"11","key":"9119_CR78","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1177\/09612033211034559","volume":"30","author":"S Vordenb\u00e4umen","year":"2021","unstructured":"Vordenb\u00e4umen S et al (2021) Methyl donor micronutrients, CD40-ligand methylation and disease activity in systemic lupus erythematosus: a cross-sectional association study. Lupus 30(11):1773\u20131780","journal-title":"Lupus"},{"issue":"1","key":"9119_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-024-00650-y","volume":"15","author":"AA Vieira","year":"2024","unstructured":"Vieira AA et al (2024) Female-bias in systemic lupus erythematosus: how much is the X chromosome to blame? Biol Sex Differ 15(1):76","journal-title":"Biol Sex Differ"},{"issue":"9","key":"9119_CR80","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.4049\/jimmunol.179.9.6352","volume":"179","author":"Q Lu","year":"2007","unstructured":"Lu Q et al (2007) Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 179(9):6352\u20136358","journal-title":"J Immunol"},{"issue":"11","key":"9119_CR81","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/s41423-022-00933-7","volume":"19","author":"F Xiao","year":"2022","unstructured":"Xiao F et al (2022) Epigenetic regulation of B cells and its role in autoimmune pathogenesis. Cell Mol Immunol 19(11):1215\u20131234","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"9119_CR82","doi-asserted-by":"publisher","first-page":"e126751","DOI":"10.1172\/jci.insight.126751","volume":"4","author":"CM Syrett","year":"2019","unstructured":"Syrett CM et al (2019) Altered X-chromosome inactivation in T cells May promote sex-biased autoimmune diseases. JCI Insight 4(7):e126751","journal-title":"JCI Insight"},{"issue":"1","key":"9119_CR83","doi-asserted-by":"publisher","first-page":"10527","DOI":"10.1038\/s41467-024-54110-7","volume":"15","author":"B Gylemo","year":"2024","unstructured":"Gylemo B et al (2024) A landscape of X-inactivation during human T cell development. Nat Commun 15(1):10527","journal-title":"Nat Commun"},{"issue":"12","key":"9119_CR84","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.4049\/jimmunol.0904060","volume":"184","author":"W Pan","year":"2010","unstructured":"Pan W et al (2010) MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4\u2009+\u2009T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol 184(12):6773\u20136781","journal-title":"J Immunol"},{"issue":"5","key":"9119_CR85","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/art.30192","volume":"63","author":"A Ceribelli","year":"2011","unstructured":"Ceribelli A et al (2011) Lupus T cells switched on by DNA hypomethylation via micrornas? Arthritis Rheum 63(5):1177","journal-title":"Arthritis Rheum"},{"issue":"2","key":"9119_CR86","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/ijms25021019","volume":"25","author":"Y Araki","year":"2024","unstructured":"Araki Y, Mimura T (2024) Epigenetic dysregulation in the pathogenesis of systemic lupus erythematosus. Int J Mol Sci 25(2):1019","journal-title":"Int J Mol Sci"},{"issue":"6","key":"9119_CR87","doi-asserted-by":"publisher","first-page":"103584","DOI":"10.1016\/j.autrev.2024.103584","volume":"23","author":"MG Danieli","year":"2024","unstructured":"Danieli MG et al (2024) Exposome: epigenetics and autoimmune diseases. Autoimmun Rev 23(6):103584","journal-title":"Autoimmun Rev"},{"issue":"7","key":"9119_CR88","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00018-022-04396-x","volume":"79","author":"K Joshi","year":"2022","unstructured":"Joshi K et al (2022) Mechanisms that regulate the activities of TET proteins. Cell Mol Life Sci 79(7):363","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"9119_CR89","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.autrev.2008.07.043","volume":"8","author":"G Gorelik","year":"2009","unstructured":"Gorelik G, Richardson B (2009) Aberrant T cell ERK pathway signaling and chromatin structure in lupus. Autoimmun Rev 8(3):196\u2013198","journal-title":"Autoimmun Rev"},{"issue":"4","key":"9119_CR90","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/gene.2008.29","volume":"9","author":"AH Sawalha","year":"2008","unstructured":"Sawalha AH et al (2008) Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun 9(4):368\u2013378","journal-title":"Genes Immun"},{"issue":"6","key":"9119_CR91","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/art.38427","volume":"66","author":"Y Li","year":"2014","unstructured":"Li Y et al (2014) Oxidative stress, T cell DNA methylation, and lupus. Arthritis Rheumatol 66(6):1574\u20131582","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"9119_CR92","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13148-024-01792-x","volume":"16","author":"MK Horton","year":"2024","unstructured":"Horton MK et al (2024) Changes in DNA methylation are associated with systemic lupus erythematosus flare remission and clinical subtypes. Clin Epigenetics 16(1):181","journal-title":"Clin Epigenetics"},{"issue":"11","key":"9119_CR93","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.immuni.2024.09.004","volume":"57","author":"S Caielli","year":"2024","unstructured":"Caielli S et al (2024) Type I IFN drives unconventional IL-1\u03b2 secretion in lupus monocytes. Immunity 57(11):2497\u20132513e12","journal-title":"Immunity"},{"key":"9119_CR94","doi-asserted-by":"publisher","first-page":"894847","DOI":"10.3389\/fimmu.2022.894847","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, Tao X, Tao J (2022) Strategies of targeting inflammasome in the treatment of systemic lupus erythematosus. Front Immunol 13:894847","journal-title":"Front Immunol"},{"key":"9119_CR95","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.2340\/actadv.v102.2293","volume":"102","author":"K M\u00e4h\u00f6nen","year":"2022","unstructured":"M\u00e4h\u00f6nen K et al (2022) Activation of NLRP3 inflammasome in the skin of patients with systemic and cutaneous lupus erythematosus. Acta Dermato-Venereologica 102:2293","journal-title":"Acta Dermato-Venereologica"},{"issue":"2","key":"9119_CR96","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/ard-2022-222653","volume":"82","author":"M Zhao","year":"2023","unstructured":"Zhao M et al (2023) 3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus. Ann Rheum Dis 82(2):226\u2013234","journal-title":"Ann Rheum Dis"},{"issue":"6704","key":"9119_CR97","doi-asserted-by":"publisher","first-page":"eadd8394","DOI":"10.1126\/science.add8394","volume":"385","author":"A Oguchi","year":"2024","unstructured":"Oguchi A et al (2024) An atlas of transcribed enhancers across helper T cell diversity for decoding human diseases. Science 385(6704):eadd8394","journal-title":"Science"},{"issue":"1","key":"9119_CR98","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/0961203320965690","volume":"30","author":"S Vordenb\u00e4umen","year":"2021","unstructured":"Vordenb\u00e4umen S et al (2021) Associations of site-specific CD4+-T-cell hypomethylation within CD40-ligand promotor and enhancer regions with disease activity of women with systemic lupus erythematosus. Lupus 30(1):45\u201351","journal-title":"Lupus"},{"key":"9119_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103137","volume":"142","author":"EC Somers","year":"2024","unstructured":"Somers EC et al (2024) Associations between CD70 methylation of T cell DNA and age in adults with systemic lupus erythematosus and population controls: the Michigan Lupus Epidemiology & Surveillance (MILES) program. J Autoimmun 142:103137","journal-title":"J Autoimmun"},{"key":"9119_CR100","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.imlet.2021.09.007","volume":"240","author":"P Gautam","year":"2021","unstructured":"Gautam P, Sharma A, Bhatnagar A (2021) Global histone modification analysis reveals hypoacetylated H3 and H4 histones in B cells from systemic lupus erythematosus patients. Immunol Lett 240:41\u201345","journal-title":"Immunol Lett"},{"key":"9119_CR101","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2119\/molmed.2011.00055","volume":"17","author":"CM Reilly","year":"2011","unstructured":"Reilly CM, Regna N, Mishra N (2011) HDAC inhibition in lupus models. Mol Med 17:417\u2013425","journal-title":"Mol Med"},{"issue":"4","key":"9119_CR102","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI16153","volume":"111","author":"N Mishra","year":"2003","unstructured":"Mishra N et al (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr\/lpr mouse. J Clin Investig 111(4):539\u2013552","journal-title":"J Clin Investig"},{"issue":"2","key":"9119_CR103","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7150\/ijms.5.73","volume":"5","author":"E Tili","year":"2008","unstructured":"Tili E, Michaille J-J, Calin GA (2008) Expression and function of micro RNAs in immune cells during normal or disease state. Int J Med Sci 5(2):73","journal-title":"Int J Med Sci"},{"issue":"16","key":"9119_CR104","doi-asserted-by":"publisher","first-page":"12767","DOI":"10.3390\/ijms241612767","volume":"24","author":"I Gilyazova","year":"2023","unstructured":"Gilyazova I et al (2023) MiRNA-146a\u2014a key player in immunity and diseases. Int J Mol Sci 24(16):12767","journal-title":"Int J Mol Sci"},{"issue":"7","key":"9119_CR105","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/08916934.2016.1171854","volume":"49","author":"R Park","year":"2016","unstructured":"Park R, Lee WJ, Ji JD (2016) Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: a meta-analysis. Autoimmunity 49(7):451\u2013458","journal-title":"Autoimmunity"},{"issue":"9","key":"9119_CR106","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.cellsig.2013.05.006","volume":"25","author":"C-g Miao","year":"2013","unstructured":"Miao C-g et al (2013) The emerging role of MicroRNAs in the pathogenesis of systemic lupus erythematosus. Cell Signal 25(9):1828\u20131836","journal-title":"Cell Signal"},{"key":"9119_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103477","author":"Y Deng","year":"2021","unstructured":"Deng Y et al (2021) Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103477","journal-title":"EBioMedicine"},{"issue":"6","key":"9119_CR108","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/0961203313499419","volume":"23","author":"EC Somers","year":"2014","unstructured":"Somers EC, Richardson B (2014) Environmental exposures, epigenetic changes and the risk of lupus. Lupus 23(6):568\u2013576","journal-title":"Lupus"},{"key":"9119_CR109","first-page":"1104","volume":"42","author":"C Cardelli","year":"2024","unstructured":"Cardelli C et al (2024) Environment and systemic lupus erythematosus. Clin Exp Rheumatol 42:1104\u20131114","journal-title":"Clin Exp Rheumatol"},{"key":"9119_CR110","doi-asserted-by":"publisher","first-page":"939594","DOI":"10.3389\/fmed.2022.939594","volume":"9","author":"B Klein","year":"2022","unstructured":"Klein B, Kunz M (2022) Current concepts of photosensitivity in cutaneous lupus erythematosus. Front Med 9:939594","journal-title":"Front Med"},{"issue":"1","key":"9119_CR111","doi-asserted-by":"publisher","first-page":"7908","DOI":"10.1038\/s41598-020-64865-w","volume":"10","author":"S Skopelja-Gardner","year":"2020","unstructured":"Skopelja-Gardner S et al (2020) The early local and systemic type I interferon responses to ultraviolet B light exposure are cGAS dependent. Sci Rep 10(1):7908","journal-title":"Sci Rep"},{"issue":"2","key":"9119_CR112","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jmb.2019.11.016","volume":"432","author":"J Maelfait","year":"2020","unstructured":"Maelfait J, Liverpool L, Rehwinkel J (2020) Nucleic acid sensors and programmed cell death. J Mol Biol 432(2):552\u2013568","journal-title":"J Mol Biol"},{"issue":"12","key":"9119_CR113","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1002\/art.20798","volume":"50","author":"KA Kirou","year":"2004","unstructured":"Kirou KA et al (2004) Coordinate overexpression of interferon-\u03b1\u2013induced genes in systemic lupus erythematosus. Arthr Rhuem 50(12):3958\u20133967","journal-title":"Arthr Rhuem"},{"issue":"4","key":"9119_CR114","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.39987","volume":"69","author":"C Sontheimer","year":"2017","unstructured":"Sontheimer C, Liggitt D, Elkon KB (2017) Ultraviolet B irradiation causes stimulator of interferon genes\u2013dependent production of protective type I interferon in mouse skin by recruited inflammatory monocytes. Arthritis Rheumatol 69(4):826\u2013836","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"9119_CR115","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.berh.2017.10.003","volume":"31","author":"AA Bengtsson","year":"2017","unstructured":"Bengtsson AA, R\u00f6nnblom L (2017) Role of interferons in SLE. Best Pract Res Clin Rheumatol 31(3):415\u2013428","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"9119_CR116","first-page":"370516","volume":"2012","author":"AH Draborg","year":"2012","unstructured":"Draborg AH, Duus K, Houen G (2012) Epstein-Barr virus and systemic lupus erythematosus. J Immunol Res 2012(1):370516","journal-title":"J Immunol Res"},{"key":"9119_CR117","doi-asserted-by":"publisher","first-page":"830993","DOI":"10.3389\/fimmu.2022.830993","volume":"13","author":"V Laurynenka","year":"2022","unstructured":"Laurynenka V et al (2022) A high prevalence of anti-EBNA1 heteroantibodies in systemic lupus erythematosus (SLE) supports anti-EBNA1 as an origin for SLE autoantibodies. Front Immunol 13:830993","journal-title":"Front Immunol"},{"issue":"6","key":"9119_CR118","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/joim.13448","volume":"291","author":"JM Woo","year":"2022","unstructured":"Woo JM et al (2022) The role of environmental exposures and gene\u2013environment interactions in the etiology of systemic lupus erythematous. J Intern Med 291(6):755\u2013778","journal-title":"J Intern Med"},{"key":"9119_CR119","doi-asserted-by":"publisher","first-page":"606936","DOI":"10.3389\/fimmu.2020.606936","volume":"11","author":"ME Munroe","year":"2021","unstructured":"Munroe ME et al (2021) Epstein-Barr functional mimicry: pathogenicity of oncogenic latent membrane protein-1 in systemic lupus erythematosus and autoimmunity. Front Immunol 11:606936","journal-title":"Front Immunol"},{"issue":"4","key":"9119_CR120","first-page":"6073","volume":"8","author":"Y Ding","year":"2015","unstructured":"Ding Y et al (2015) The expression of EBV-encoded LMP1 in young patients with lupus nephritis. Int J Clin Exp Med 8(4):6073","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"9119_CR121","doi-asserted-by":"publisher","first-page":"20236","DOI":"10.1038\/s41598-024-70913-6","volume":"14","author":"YB Lemus","year":"2024","unstructured":"Lemus YB et al (2024) Gene profiling of Epstein-Barr virus and human endogenous retrovirus in peripheral blood mononuclear cells of SLE patients: immune response implications. Sci Rep 14(1):20236","journal-title":"Sci Rep"},{"key":"9119_CR122","doi-asserted-by":"publisher","first-page":"623944","DOI":"10.3389\/fimmu.2020.623944","volume":"11","author":"NR Jog","year":"2021","unstructured":"Jog NR, James JA (2021) Epstein barr virus and autoimmune responses in systemic lupus erythematosus. Front Immunol 11:623944","journal-title":"Front Immunol"},{"issue":"2","key":"9119_CR123","doi-asserted-by":"publisher","first-page":"e1178","DOI":"10.1002\/iid3.1178","volume":"12","author":"BA Suliman","year":"2024","unstructured":"Suliman BA (2024) Potential clinical implications of molecular mimicry-induced autoimmunity. Immun Inflamm Dis 12(2):e1178","journal-title":"Immun Inflamm Dis"},{"issue":"5438","key":"9119_CR124","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1126\/science.286.5438.300","volume":"286","author":"J Uchida","year":"1999","unstructured":"Uchida J et al (1999) Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286(5438):300\u2013303","journal-title":"Science"},{"issue":"1","key":"9119_CR125","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1128\/CMR.9.1.72","volume":"9","author":"HB Urnovitz","year":"1996","unstructured":"Urnovitz HB, Murphy WH (1996) Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin Microbiol Rev 9(1):72\u201399","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"9119_CR126","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4149\/av_2014_03_199","volume":"58","author":"L Rogo","year":"2014","unstructured":"Rogo L et al (2014) Human parvovirus B19: a review. Acta Virol 58(3):199\u2013213","journal-title":"Acta Virol"},{"issue":"2","key":"9119_CR127","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/v13020277","volume":"13","author":"M Quaglia","year":"2021","unstructured":"Quaglia M et al (2021) Viral infections and systemic lupus erythematosus: new players in an old story. Viruses 13(2):277","journal-title":"Viruses"},{"issue":"suppl 5","key":"9119_CR128","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1289\/ehp.99107s5793","volume":"107","author":"CG Parks","year":"1999","unstructured":"Parks CG, Conrad K, Cooper GS (1999) Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 107(suppl 5):793\u2013802","journal-title":"Environ Health Perspect"},{"issue":"1","key":"9119_CR129","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.35248\/2684-1630.16.1.102","volume":"1","author":"RA Norman","year":"2016","unstructured":"Norman RA (2016) The history of lupus erythematosus and discoid lupus: from Hippocrates to the present. Lupus Open Access 1(1):2684 -1630.16","journal-title":"Lupus Open Access"},{"key":"9119_CR130","doi-asserted-by":"crossref","unstructured":"Richardson B, Somers EC (2021) Environmental and drug-induced lupus, in Lahita\u2019s Systemic Lupus Erythematosus. Elsevier, pp 381\u2013388","DOI":"10.1016\/B978-0-12-820583-9.00046-4"},{"issue":"3","key":"9119_CR131","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.berh.2017.09.005","volume":"31","author":"CG Parks","year":"2017","unstructured":"Parks CG et al (2017) Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 31(3):306\u2013320","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"9119_CR132","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1567-5769(01)00045-5","volume":"1","author":"RW McMurray","year":"2001","unstructured":"McMurray RW (2001) Estrogen, prolactin, and autoimmunity: actions and interactions. Int Immunopharmacol 1(6):995\u20131008","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"9119_CR133","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2174\/1568010043483944","volume":"3","author":"ML Salem","year":"2004","unstructured":"Salem ML (2004) Estrogen, a double-edged sword: modulation of TH1-and TH2-mediated inflammations by differential regulation of TH1\/TH2 cytokine production. Current Drug Target -Inflammation & Allergy 3(1):97\u2013104","journal-title":"Current Drug Target -Inflammation & Allergy"},{"key":"9119_CR134","unstructured":"Khan D (2012) Molecular Basis of Upregulation of IL-17 in Estrogen Model of Inflammation."},{"issue":"11","key":"9119_CR135","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/j.immuni.2023.10.008","volume":"56","author":"JP Hoffmann","year":"2023","unstructured":"Hoffmann JP et al (2023) Sex hormone signaling and regulation of immune function. Immunity 56(11):2472\u20132491","journal-title":"Immunity"},{"key":"9119_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2024.104295","author":"H Alanazi","year":"2024","unstructured":"Alanazi H et al (2024) The impact of reproductive hormones on T cell immunity; normal and assisted reproductive cycles. J Reprod Immunol. https:\/\/doi.org\/10.1016\/j.jri.2024.104295","journal-title":"J Reprod Immunol"},{"issue":"2","key":"9119_CR137","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/immu.200310027","volume":"33","author":"A Maret","year":"2003","unstructured":"Maret A et al (2003) Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of Estrogen receptor \u03b1 expression in hematopoietic cells. Eur J Immunol 33(2):512\u2013521","journal-title":"Eur J Immunol"},{"key":"9119_CR138","doi-asserted-by":"publisher","first-page":"654912","DOI":"10.3389\/fmed.2021.654912","volume":"8","author":"FC Paquissi","year":"2021","unstructured":"Paquissi FC, Abensur H (2021) The Th17\/IL-17 axis and kidney diseases, with focus on lupus nephritis. Front Med 8:654912","journal-title":"Front Med"},{"key":"9119_CR139","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12016-009-8185-3","volume":"40","author":"LJ Jara","year":"2011","unstructured":"Jara LJ et al (2011) Prolactin and autoimmunity. Clin Rev Allergy Immunol 40:50\u201359","journal-title":"Clin Rev Allergy Immunol"},{"key":"9119_CR140","doi-asserted-by":"publisher","first-page":"370132","DOI":"10.3389\/fimmu.2018.00794","volume":"9","author":"MR Gubbels Bupp","year":"2018","unstructured":"Gubbels Bupp MR, Jorgensen TN (2018) Androgen-induced immunosuppression. Front Immunol 9:370132","journal-title":"Front Immunol"},{"issue":"2","key":"9119_CR141","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1191\/0961203303lu334oa","volume":"12","author":"M Arbuckle","year":"2003","unstructured":"Arbuckle M et al (2003) Rapid clinical progression to diagnosis among African-American men with systemic lupus erythematosus. Lupus 12(2):99\u2013106","journal-title":"Lupus"},{"issue":"4","key":"9119_CR142","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3899\/jrheum.111061","volume":"39","author":"TC Tan","year":"2012","unstructured":"Tan TC et al (2012) Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rhuematol 39(4):759\u2013769","journal-title":"J Rhuematol"},{"issue":"5","key":"9119_CR143","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/tre.876","volume":"13","author":"R Thomas","year":"2022","unstructured":"Thomas R, Jawad AS (2022) Systemic lupus erythematosus: rarer in men than women but more severe. Trends Urol Men\u2019s Health 13(5):11\u201314","journal-title":"Trends Urol Men\u2019s Health"},{"issue":"6","key":"9119_CR144","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrrheum.2012.58","volume":"8","author":"JE Craft","year":"2012","unstructured":"Craft JE (2012) Follicular helper T cells in immunity and systemic autoimmunity. Nat Rev Rheumatol 8(6):337\u2013347","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"9119_CR145","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","volume":"165","author":"R Banchereau","year":"2016","unstructured":"Banchereau R et al (2016) Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165(3):551\u2013565","journal-title":"Cell"},{"issue":"Supplement6","key":"9119_CR146","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/rheumatology\/kez387","volume":"58","author":"S Frizinsky","year":"2019","unstructured":"Frizinsky S et al (2019) The innate immune perspective of autoimmune and autoinflammatory conditions. Rheumatology 58(Supplement6):vi1\u2013vi8","journal-title":"Rheumatology"},{"issue":"5","key":"9119_CR147","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrrheum.2010.46","volume":"6","author":"LE Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz LE et al (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6(5):280\u2013289","journal-title":"Nat Rev Rheumatol"},{"key":"9119_CR148","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s10753-020-01294-x","volume":"43","author":"Z Cahilog","year":"2020","unstructured":"Cahilog Z et al (2020) The role of neutrophil NETosis in organ injury: novel inflammatory cell death mechanisms. Inflammation 43:2021\u20132032","journal-title":"Inflammation"},{"issue":"5","key":"9119_CR149","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/0961203308090020","volume":"17","author":"L R\u00f6nnblom","year":"2008","unstructured":"R\u00f6nnblom L, Pascual V (2008) The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17(5):394\u2013399","journal-title":"Lupus"},{"issue":"6","key":"9119_CR150","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","volume":"190","author":"CB Xie","year":"2020","unstructured":"Xie CB, Jane-Wit D, Pober JS (2020) Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets. Am J Pathol 190(6):1138\u20131150","journal-title":"Am J Pathol"},{"issue":"2","key":"9119_CR151","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000431278","volume":"1","author":"L Bao","year":"2015","unstructured":"Bao L, Cunningham PN, Quigg RJ (2015) Complement in lupus nephritis: new perspectives. Kidney Dis 1(2):91\u201399","journal-title":"Kidney Dis"},{"key":"9119_CR152","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fimmu.2014.00402","volume":"5","author":"SS Bohlson","year":"2014","unstructured":"Bohlson SS et al (2014) Complement, c1q, and c1q-related molecules regulate macrophage polarization. Front Immunol 5:402","journal-title":"Front Immunol"},{"issue":"2","key":"9119_CR153","first-page":"107","volume":"50","author":"H Lutz","year":"2004","unstructured":"Lutz H (2004) Innate immune and non-immune mediators of erythrocyte clearance. Cell Mol Biol 50(2):107\u2013116","journal-title":"Cell Mol Biol"},{"key":"9119_CR154","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fimmu.2015.00317","volume":"6","author":"L Kouser","year":"2015","unstructured":"Kouser L et al (2015) Emerging and novel functions of complement protein C1q. Front Immunol 6:317","journal-title":"Front Immunol"},{"issue":"5","key":"9119_CR155","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s12276-022-00774-4","volume":"54","author":"M Son","year":"2022","unstructured":"Son M (2022) Understanding the contextual functions of C1q and LAIR-1 and their applications. Exp Mol Med 54(5):567\u2013572","journal-title":"Exp Mol Med"},{"issue":"12","key":"9119_CR156","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.it.2016.10.003","volume":"37","author":"BA Heesters","year":"2016","unstructured":"Heesters BA et al (2016) Antigen presentation to B cells. Trends Immunol 37(12):844\u2013854","journal-title":"Trends Immunol"},{"issue":"8","key":"9119_CR157","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/08916930701510673","volume":"40","author":"L Truedsson","year":"2007","unstructured":"Truedsson L, Bengtsson AA, Sturfelt G (2007) Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40(8):560\u2013566","journal-title":"Autoimmunity"},{"issue":"8","key":"9119_CR158","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","volume":"19","author":"ES Reis","year":"2019","unstructured":"Reis ES et al (2019) New insights into the immune functions of complement. Nat Rev Immunol 19(8):503\u2013516","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"9119_CR159","doi-asserted-by":"publisher","first-page":"8502","DOI":"10.18632\/oncotarget.23907","volume":"9","author":"M-H Tseng","year":"2018","unstructured":"Tseng M-H et al (2018) Serum complement factor I is associated with disease activity of systemic lupus erythematosus. Oncotarget 9(9):8502","journal-title":"Oncotarget"},{"issue":"8","key":"9119_CR160","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.3390\/ijms22084190","volume":"22","author":"D Bencze","year":"2021","unstructured":"Bencze D, Fekete T, P\u00e1zm\u00e1ndi K (2021) Type I interferon production of plasmacytoid dendritic cells under control. Int J Mol Sci 22(8):4190","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9119_CR161","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","volume":"14","author":"MK Crow","year":"2019","unstructured":"Crow MK, Olferiev M, Kirou KA (2019) Type I interferons in autoimmune disease. Annu Rev Pathol 14(1):369\u2013393","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"9119_CR162","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1084\/jem.20051696","volume":"202","author":"Jr Vollmer","year":"2005","unstructured":"Vollmer Jr et al (2005) Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 202(11):1575\u20131585","journal-title":"J Exp Med"},{"issue":"13","key":"9119_CR163","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1177\/0961203319885447","volume":"28","author":"P Brohawn","year":"2019","unstructured":"Brohawn P et al (2019) Type I interferon gene signature test\u2013low and\u2013high patients with systemic lupus erythematosus have distinct gene expression signatures. Lupus 28(13):1524\u20131533","journal-title":"Lupus"},{"issue":"7","key":"9119_CR164","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.3390\/cimb45070378","volume":"45","author":"M Sestan","year":"2023","unstructured":"Sestan M et al (2023) The role of genetic risk factors in pathogenesis of childhood-onset systemic lupus erythematosus. Curr Issues Mol Biol 45(7):5981\u20136002","journal-title":"Curr Issues Mol Biol"},{"issue":"2","key":"9119_CR165","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1172\/JCI23025","volume":"115","author":"TK Means","year":"2005","unstructured":"Means TK et al (2005) Human lupus autoantibody\u2013DNA complexes activate DCs through Cooperation of CD32 and TLR9. J Clin Investig 115(2):407\u2013417","journal-title":"J Clin Investig"},{"issue":"3","key":"9119_CR166","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","volume":"25","author":"J Banchereau","year":"2006","unstructured":"Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25(3):383\u2013392","journal-title":"Immunity"},{"key":"9119_CR167","doi-asserted-by":"publisher","first-page":"102856","DOI":"10.1016\/j.jaut.2022.102856","volume":"132","author":"J Liu","year":"2022","unstructured":"Liu J, Zhang X, Cao X (2022) Dendritic cells in systemic lupus erythematosus: from pathogenesis to therapeutic applications. J Autoimmun 132:102856","journal-title":"J Autoimmun"},{"issue":"4 Suppl 98","key":"9119_CR168","first-page":"21","volume":"34","author":"L Ronnblom","year":"2016","unstructured":"Ronnblom L (2016) The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol 34(4 Suppl 98):21\u201324","journal-title":"Clin Exp Rheumatol"},{"issue":"24","key":"9119_CR169","doi-asserted-by":"publisher","first-page":"15998","DOI":"10.3390\/ijms232415998","volume":"23","author":"B Infante","year":"2022","unstructured":"Infante B et al (2022) Unraveling the link between interferon-\u03b1 and systemic lupus erythematosus: from the molecular mechanisms to target therapies. Int J Mol Sci 23(24):15998","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9119_CR170","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0002-9440(10)61689-6","volume":"159","author":"L Farkas","year":"2001","unstructured":"Farkas L et al (2001) Plasmacytoid dendritic cells (natural interferon-\u03b1\/\u03b2-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 159(1):237\u2013243","journal-title":"Am J Pathol"},{"issue":"6","key":"9119_CR171","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/PAP.0b013e3181bb6bc2","volume":"16","author":"AG Jegalian","year":"2009","unstructured":"Jegalian AG, Facchetti F, Jaffe ES (2009) Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv Anat Pathol 16(6):392\u2013404","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"9119_CR172","doi-asserted-by":"publisher","first-page":"e36761","DOI":"10.1371\/journal.pone.0036761","volume":"7","author":"E Pau","year":"2012","unstructured":"Pau E et al (2012) TLR tolerance reduces IFN-alpha production despite plasmacytoid dendritic cell expansion and anti-nuclear antibodies in NZB bicongenic mice. PLoS ONE 7(5):e36761","journal-title":"PLoS ONE"},{"issue":"5","key":"9119_CR173","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1038\/cti.2016.26","volume":"5","author":"S Oon","year":"2016","unstructured":"Oon S, Wilson NJ, Wicks I (2016) Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Translational Immunol 5(5):e79","journal-title":"Clin Translational Immunol"},{"issue":"1","key":"9119_CR174","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2796.2008.02050.x","volume":"265","author":"C Guiducci","year":"2009","unstructured":"Guiducci C, Coffman R, Barrat F (2009) Signalling pathways leading to IFN-\u03b1 production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 265(1):43\u201357","journal-title":"J Intern Med"},{"issue":"12","key":"9119_CR175","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.autrev.2012.03.004","volume":"11","author":"VS-F Chan","year":"2012","unstructured":"Chan VS-F et al (2012) Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev 11(12):890\u2013897","journal-title":"Autoimmun Rev"},{"key":"9119_CR176","doi-asserted-by":"crossref","unstructured":"Devi KSP, Anandasabapathy N (2017) The origin of DCs and capacity for Immunologic tolerance In central and peripheral tissues. In Seminars In immunopathology. Springer","DOI":"10.1007\/s00281-016-0602-0"},{"issue":"2","key":"9119_CR177","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/1756-185X.12532","volume":"18","author":"MY Mok","year":"2015","unstructured":"Mok MY (2015) Tolerogenic dendritic cells: role and therapeutic implications in systemic lupus erythematosus. Int J Rheum Dis 18(2):250\u2013259","journal-title":"Int J Rheum Dis"},{"issue":"5546","key":"9119_CR178","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1126\/science.1064890","volume":"294","author":"P Blanco","year":"2001","unstructured":"Blanco P et al (2001) Induction of dendritic cell differentiation by IFN-\u03b1 in systemic lupus erythematosus. Science 294(5546):1540\u20131543","journal-title":"Science"},{"issue":"4","key":"9119_CR179","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1365-2567.2012.03598.x","volume":"136","author":"AA Herrada","year":"2012","unstructured":"Herrada AA et al (2012) Haem Oxygenase 1 expression is altered in monocytes from patients with systemic lupus erythematosus. Immunology 136(4):414\u2013424","journal-title":"Immunology"},{"key":"9119_CR180","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s10753-014-9908-z","volume":"37","author":"B-Z Li","year":"2014","unstructured":"Li B-Z et al (2014) Therapeutic potential of HO-1 in autoimmune diseases. Inflammation 37:1779\u20131788","journal-title":"Inflammation"},{"issue":"1","key":"9119_CR181","doi-asserted-by":"publisher","first-page":"ltad012","DOI":"10.1093\/immadv\/ltad012","volume":"3","author":"MJ Mansilla","year":"2023","unstructured":"Mansilla MJ, Hilkens CM, Mart\u00ednez-C\u00e1ceres EM (2023) Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration. Immunotherapy Adv 3(1):ltad012","journal-title":"Immunotherapy Adv"},{"issue":"12","key":"9119_CR182","doi-asserted-by":"publisher","first-page":"F59","DOI":"10.1084\/jem.194.12.f59","volume":"194","author":"L R\u00f6nnblom","year":"2001","unstructured":"R\u00f6nnblom L, Alm GV (2001) A pivotal role for the natural interferon \u03b1\u2013producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 194(12):F59\u2013F64","journal-title":"J Exp Med"},{"key":"9119_CR183","unstructured":"Becker A (2023) Exploring the modulation and development of type 3 dendritic cells in cancer and autoimmunity. Sl: sn"},{"key":"9119_CR184","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.jaut.2019.102359","volume":"110","author":"MD Catalina","year":"2020","unstructured":"Catalina MD et al (2020) The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus. J Autoimmun 110:102359","journal-title":"J Autoimmun"},{"issue":"12","key":"9119_CR185","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrrheum.2011.132","volume":"7","author":"MJ Kaplan","year":"2011","unstructured":"Kaplan MJ (2011) Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 7(12):691\u2013699","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"9119_CR186","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nri.2017.105","volume":"18","author":"V Papayannopoulos","year":"2018","unstructured":"Papayannopoulos V (2018) Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol 18(2):134\u2013147","journal-title":"Nat Rev Immunol"},{"key":"9119_CR187","doi-asserted-by":"crossref","unstructured":"Reshetnyak T, Nurbaeva K (2023) The role of neutrophil extracellular traps (NETs) in the pathogenesis of systemic lupus erythematosus and antiphospholipid syndrome. MDPI. p. 13581","DOI":"10.3390\/ijms241713581"},{"key":"9119_CR188","doi-asserted-by":"crossref","unstructured":"Carmona-Rivera C, Kaplan MJ (2013) Low-density granulocytes: a distinct class of neutrophils In systemic autoimmunity. In Seminars In immunopathology. Springer","DOI":"10.1007\/s00281-013-0375-7"},{"key":"9119_CR189","unstructured":"Schultinga A (2019) Low Density Granulocytes (LDG) in the pathogenesis of Systemic Lupus Erythematosus (SLE): Targets for therapy?"},{"issue":"2","key":"9119_CR190","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12016-020-08804-7","volume":"61","author":"V Mutua","year":"2021","unstructured":"Mutua V, Gershwin LJ (2021) A review of neutrophil extracellular traps (NETs) in disease: potential anti-NETs therapeutics. Clin Rev Allergy Immunol 61(2):194\u2013211","journal-title":"Clin Rev Allergy Immunol"},{"key":"9119_CR191","doi-asserted-by":"crossref","unstructured":"Zawrotniak M, R\u0105pa\u0142a-Kozik M (2013) Neutrophil extracellular traps (NETs): formation and implications.","DOI":"10.18388\/abp.2013_1983"},{"issue":"8","key":"9119_CR192","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nri3865","volume":"15","author":"M Swiecki","year":"2015","unstructured":"Swiecki M, Colonna M (2015) The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 15(8):471\u2013485","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"9119_CR193","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3390\/cells10102667","volume":"10","author":"A Angeletti","year":"2021","unstructured":"Angeletti A et al (2021) Neutrophil extracellular traps-DNase balance and autoimmunity. Cells 10(10):2667","journal-title":"Cells"},{"issue":"2","key":"9119_CR194","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/nm.4027","volume":"22","author":"C Lood","year":"2016","unstructured":"Lood C et al (2016) Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med 22(2):146\u2013153","journal-title":"Nat Med"},{"issue":"11","key":"9119_CR195","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","volume":"20","author":"M Motwani","year":"2019","unstructured":"Motwani M, Pesiridis S, Fitzgerald KA (2019) DNA sensing by the cGAS\u2013STING pathway in health and disease. Nat Rev Genet 20(11):657\u2013674","journal-title":"Nat Rev Genet"},{"issue":"8\u20139","key":"9119_CR196","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.dnarep.2004.03.002","volume":"3","author":"A Barzilai","year":"2004","unstructured":"Barzilai A, Yamamoto K-I (2004) DNA damage responses to oxidative stress. DNA Repair 3(8\u20139):1109\u20131115","journal-title":"DNA Repair"},{"issue":"1","key":"9119_CR197","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/imm.13423","volume":"165","author":"A Singhal","year":"2022","unstructured":"Singhal A, Kumar S (2022) Neutrophil and remnant clearance in immunity and inflammation. Immunology 165(1):22\u201343","journal-title":"Immunology"},{"issue":"1","key":"9119_CR198","doi-asserted-by":"publisher","first-page":"e000399","DOI":"10.1136\/lupus-2020-000399","volume":"7","author":"A Meyer","year":"2020","unstructured":"Meyer A et al (2020) Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations. Lupus Sci Med 7(1):e000399","journal-title":"Lupus Sci Med"},{"key":"9119_CR199","doi-asserted-by":"publisher","first-page":"110846","DOI":"10.1016\/j.intimp.2023.110846","volume":"124","author":"R Yadav","year":"2023","unstructured":"Yadav R, Momin A, Godugu C (2023) DNase based therapeutic approaches for the treatment of NETosis related inflammatory diseases. Int Immunopharmacol 124:110846","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"9119_CR200","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1189\/jlb.5BT0615-234R","volume":"99","author":"A Barnado","year":"2016","unstructured":"Barnado A, Crofford LJ, Oates JC (2016) At the bedside: neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J Leukoc Biol 99(2):265\u2013278","journal-title":"J Leukoc Biol"},{"issue":"7966","key":"9119_CR201","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41586-023-06002-x","volume":"618","author":"T Lazarov","year":"2023","unstructured":"Lazarov T et al (2023) Physiology and diseases of tissue-resident macrophages. Nature 618(7966):698\u2013707","journal-title":"Nature"},{"issue":"7","key":"9119_CR202","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H","volume":"41","author":"M Herrmann","year":"1998","unstructured":"Herrmann M et al (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthr Rhuem 41(7):1241\u20131250","journal-title":"Arthr Rhuem"},{"key":"9119_CR203","doi-asserted-by":"crossref","unstructured":"Katsiari CG, Liossis S-NC, Sfikakis PP (2010) The pathophysiologic role of monocytes and macrophages In systemic lupus erythematosus: a reappraisal. In Seminars In arthritis and rheumatism. Elsevier","DOI":"10.1016\/j.semarthrit.2008.11.002"},{"issue":"9","key":"9119_CR204","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41577-019-0167-y","volume":"19","author":"G Lemke","year":"2019","unstructured":"Lemke G (2019) How macrophages deal with death. Nat Rev Immunol 19(9):539\u2013549","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"9119_CR205","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41580-020-0232-1","volume":"21","author":"E Boada-Romero","year":"2020","unstructured":"Boada-Romero E et al (2020) The clearance of dead cells by efferocytosis. Nat Rev Mol Cell Biol 21(7):398\u2013414","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9119_CR206","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000075688","volume":"7","author":"B Ghebrehiwet\u00aa","year":"2004","unstructured":"Ghebrehiwet\u00aa B, Peerschkeb EI (2004) Role of C1q and C1q receptors in the pathogenesis of systemic lupus. Complement Autoimmun 7:87\u201397","journal-title":"Complement Autoimmun"},{"issue":"6342","key":"9119_CR207","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1126\/science.aai8132","volume":"356","author":"L Bosurgi","year":"2017","unstructured":"Bosurgi L et al (2017) Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. Science 356(6342):1072\u20131076","journal-title":"Science"},{"key":"9119_CR208","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","volume":"10","author":"M Orecchioni","year":"2019","unstructured":"Orecchioni M et al (2019) Macrophage polarization: different gene signatures in M1 (LPS+) vs. classically and M2 (LPS\u2013) vs. alternatively activated macrophages. Front Immunol 10:1084","journal-title":"Front Immunol"},{"key":"9119_CR209","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3389\/fimmu.2019.01140","volume":"10","author":"W-T Ma","year":"2019","unstructured":"Ma W-T et al (2019) The role of monocytes and macrophages in autoimmune diseases: a comprehensive review. Front Immunol 10:1140","journal-title":"Front Immunol"},{"issue":"12","key":"9119_CR210","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1177\/0961203317701842","volume":"26","author":"S Mohammadi","year":"2017","unstructured":"Mohammadi S et al (2017) Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by Pioglitazone. Lupus 26(12):1318\u20131327","journal-title":"Lupus"},{"key":"9119_CR211","doi-asserted-by":"publisher","first-page":"1169560","DOI":"10.3389\/fimmu.2023.1169560","volume":"14","author":"G Koncz","year":"2023","unstructured":"Koncz G et al (2023) Damage-mediated macrophage polarization in sterile inflammation. Front Immunol 14:1169560","journal-title":"Front Immunol"},{"issue":"7","key":"9119_CR212","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","volume":"20","author":"A Arazi","year":"2019","unstructured":"Arazi A et al (2019) The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol 20(7):902\u2013914","journal-title":"Nat Immunol"},{"key":"9119_CR213","doi-asserted-by":"crossref","unstructured":"Uzun O et al (2025) Relationship between macrophage phenotype and kidney survival in patients with lupus nephritis. Nefrolog\u00eda, : p. 101331","DOI":"10.1016\/j.nefro.2025.04.001"},{"issue":"2","key":"9119_CR214","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000431214","volume":"1","author":"X-M Meng","year":"2015","unstructured":"Meng X-M et al (2015) Macrophage phenotype in kidney injury and repair. Kidney Dis 1(2):138\u2013146","journal-title":"Kidney Dis"},{"issue":"4","key":"9119_CR215","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1159\/000430251","volume":"37","author":"F Li","year":"2015","unstructured":"Li F et al (2015) Macrophage polarization modulates development of systemic lupus erythematosus. Cell Physiol Biochem 37(4):1279\u20131288","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"9119_CR216","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.1002\/jcp.26429","volume":"233","author":"A Shapouri-Moghaddam","year":"2018","unstructured":"Shapouri-Moghaddam A et al (2018) Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol 233(9):6425\u20136440","journal-title":"J Cell Physiol"},{"key":"9119_CR217","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fimmu.2014.00614","volume":"5","author":"N Wang","year":"2014","unstructured":"Wang N, Liang H, Zen K (2014) Molecular mechanisms that influence the macrophage M1\u2013M2 polarization balance. Front Immunol 5:614","journal-title":"Front Immunol"},{"key":"9119_CR218","doi-asserted-by":"publisher","first-page":"1477708","DOI":"10.3389\/fphar.2024.1477708","volume":"15","author":"Y Cheng","year":"2024","unstructured":"Cheng Y et al (2024) Roles of macrophages in lupus nephritis. Front Pharmacol 15:1477708","journal-title":"Front Pharmacol"},{"issue":"5","key":"9119_CR219","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/gene.2009.35","volume":"10","author":"X Li","year":"2009","unstructured":"Li X et al (2009) Fc\u03b3 receptors: structure, function and role as genetic risk factors in SLE. Genes Immun 10(5):380\u2013389","journal-title":"Genes Immun"},{"key":"9119_CR220","doi-asserted-by":"crossref","unstructured":"Bournazos S, Wang TT, Ravetch JV (2017) The role and function of Fc\u03b3 receptors on myeloid cells. Myeloid Cells Health Disease: Synthesis, : p. 405\u2013427","DOI":"10.1128\/9781555819194.ch22"},{"key":"9119_CR221","doi-asserted-by":"crossref","unstructured":"Frachet P, Tacnet-Delorme P (2015) Role of C1q in Efferocytosis and Self-Tolerance With Autoimmunity. Autoimmunity: Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases, : p. 21","DOI":"10.5772\/60519"},{"key":"9119_CR222","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3389\/fimmu.2014.00674","volume":"5","author":"SQ Nagelkerke","year":"2015","unstructured":"Nagelkerke SQ, Kuijpers TW (2015) Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol 5:674","journal-title":"Front Immunol"},{"key":"9119_CR223","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fimmu.2018.00135","volume":"9","author":"S Han","year":"2018","unstructured":"Han S et al (2018) Liver X receptor agonist therapy prevents diffuse alveolar hemorrhage in murine lupus by repolarizing macrophages. Front Immunol 9:135","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR224","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-023-01687-y","volume":"9","author":"J Yao","year":"2024","unstructured":"Yao J et al (2024) The role of inflammasomes in human diseases and their potential as therapeutic targets. Signal Transduct Target Therapy 9(1):10","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"9119_CR225","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41392-024-01958-2","volume":"9","author":"Y Liu","year":"2024","unstructured":"Liu Y et al (2024) Pyroptosis in health and disease: mechanisms, regulation and clinical perspective. Signal Transduct Target Therapy 9(1):245","journal-title":"Signal Transduct Target Therapy"},{"issue":"5","key":"9119_CR226","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41577-022-00787-0","volume":"23","author":"G Wigerblad","year":"2023","unstructured":"Wigerblad G, Kaplan MJ (2023) Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol 23(5):274\u2013288","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"9119_CR227","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s12276-023-00965-7","volume":"55","author":"J Kim","year":"2023","unstructured":"Kim J, Kim H-S, Chung JH (2023) Molecular mechanisms of mitochondrial DNA release and activation of the cGAS-STING pathway. Exp Mol Med 55(3):510\u2013519","journal-title":"Exp Mol Med"},{"issue":"21","key":"9119_CR228","doi-asserted-by":"publisher","first-page":"4584","DOI":"10.3390\/nu15214584","volume":"15","author":"B Chen","year":"2023","unstructured":"Chen B, Wang Y, Chen G (2023) New potentiality of bioactive substances: regulating the NLRP3 inflammasome in autoimmune diseases. Nutrients 15(21):4584","journal-title":"Nutrients"},{"issue":"1","key":"9119_CR229","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41467-023-36522-z","volume":"14","author":"N Miao","year":"2023","unstructured":"Miao N et al (2023) Oxidized mitochondrial DNA induces gasdermin D oligomerization in systemic lupus erythematosus. Nat Commun 14(1):872","journal-title":"Nat Commun"},{"key":"9119_CR230","doi-asserted-by":"publisher","first-page":"109221","DOI":"10.1016\/j.clim.2022.109221","volume":"247","author":"F-f Chen","year":"2023","unstructured":"Chen F-f et al (2023) Renal NLRP3 inflammasome activation is associated with disease activity in lupus nephritis. Clin Immunol 247:109221","journal-title":"Clin Immunol"},{"issue":"1","key":"9119_CR231","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-021-00725-x","volume":"6","author":"M Yang","year":"2021","unstructured":"Yang M et al (2021) AIM2 deficiency in B cells ameliorates systemic lupus erythematosus by regulating Blimp-1\u2013Bcl-6 axis-mediated B-cell differentiation. Signal Transduct Target Therapy 6(1):341","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"9119_CR232","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1038\/s41598-021-84170-4","volume":"11","author":"M Xiang","year":"2021","unstructured":"Xiang M et al (2021) Correlation between Circulating interleukin-18 level and systemic lupus erythematosus: A meta-analysis. Sci Rep 11(1):4707","journal-title":"Sci Rep"},{"issue":"2","key":"9119_CR233","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/09612033211069853","volume":"31","author":"R Liang","year":"2022","unstructured":"Liang R et al (2022) Elevated serum free IL-18 in neuropsychiatric systemic lupus erythematosus patients with seizure disorders. Lupus 31(2):187\u2013193","journal-title":"Lupus"},{"issue":"12","key":"9119_CR234","doi-asserted-by":"publisher","first-page":"e188724","DOI":"10.1172\/jci.insight.188724","volume":"10","author":"R Vaineau","year":"2025","unstructured":"Vaineau R et al (2025) IL-1\u03b2 signaling modulates T follicular helper and regulatory cells in human lymphoid tissues. JCI Insight 10(12):e188724","journal-title":"JCI Insight"},{"issue":"1","key":"9119_CR235","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1186\/s12967-024-05951-9","volume":"22","author":"Y Lai","year":"2024","unstructured":"Lai Y et al (2024) Novel approach to alleviate lupus nephritis: targeting the NLRP3 inflammasome in CD8\u2009+\u2009CD69\u2009+\u2009CD103\u2009+\u2009TRM cells. J Translational Med 22(1):1139","journal-title":"J Translational Med"},{"issue":"1","key":"9119_CR236","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","volume":"20","author":"E Landy","year":"2024","unstructured":"Landy E et al (2024) Biological and clinical roles of IL-18 in inflammatory diseases. Nat Rev Rheumatol 20(1):33\u201347","journal-title":"Nat Rev Rheumatol"},{"issue":"24","key":"9119_CR237","doi-asserted-by":"publisher","first-page":"13505","DOI":"10.3390\/ijms252413505","volume":"25","author":"D Novick","year":"2024","unstructured":"Novick D (2024) IL-18 and IL-18BP: a unique dyad in health and disease. Int J Mol Sci 25(24):13505","journal-title":"Int J Mol Sci"},{"issue":"10","key":"9119_CR238","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3390\/biology9100308","volume":"9","author":"K Dossybayeva","year":"2020","unstructured":"Dossybayeva K, Abdukhakimova D, Poddighe D (2020) Basophils and systemic lupus erythematosus in murine models and human patients. Biology 9(10):308","journal-title":"Biology"},{"key":"9119_CR239","doi-asserted-by":"publisher","first-page":"1190034","DOI":"10.3389\/fimmu.2023.1190034","volume":"14","author":"R Poto","year":"2023","unstructured":"Poto R et al (2023) Basophils beyond allergic and parasitic diseases. Front Immunol 14:1190034","journal-title":"Front Immunol"},{"issue":"3","key":"9119_CR240","first-page":"142","volume":"21","author":"E Schneider","year":"2010","unstructured":"Schneider E et al (2010) Basophils: new players in the cytokine network. Eur Cytokine Netw 21(3):142\u2013153","journal-title":"Eur Cytokine Netw"},{"issue":"2","key":"9119_CR241","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1159\/000481609","volume":"43","author":"Q Pan","year":"2017","unstructured":"Pan Q et al (2017) Basophil recruitment to skin lesions of patients with systemic lupus erythematosus mediated by CCR1 and CCR2. Cell Physiol Biochem 43(2):832\u2013839","journal-title":"Cell Physiol Biochem"},{"key":"9119_CR242","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10067-017-3858-4","volume":"37","author":"P Liang","year":"2018","unstructured":"Liang P et al (2018) Low level of Circulating basophil counts in biopsy-proven active lupus nephritis. Clin Rheumatol 37:459\u2013465","journal-title":"Clin Rheumatol"},{"issue":"1","key":"9119_CR243","doi-asserted-by":"publisher","first-page":"7489","DOI":"10.1038\/s41467-022-35209-1","volume":"13","author":"M Zheng","year":"2022","unstructured":"Zheng M et al (2022) Single-cell sequencing shows cellular heterogeneity of cutaneous lesions in lupus erythematosus. Nat Commun 13(1):7489","journal-title":"Nat Commun"},{"issue":"1","key":"9119_CR244","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2014.05.004","volume":"154","author":"JC Martin","year":"2014","unstructured":"Martin JC, Baeten DL, Josien R (2014) Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clin Immunol 154(1):1\u201312","journal-title":"Clin Immunol"},{"issue":"6","key":"9119_CR245","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nm.2159","volume":"16","author":"N Charles","year":"2010","unstructured":"Charles N et al (2010) Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 16(6):701\u2013707","journal-title":"Nat Med"},{"issue":"1","key":"9119_CR246","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41467-018-03129-8","volume":"9","author":"C Pellefigues","year":"2018","unstructured":"Pellefigues C et al (2018) Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs. Nat Commun 9(1):725","journal-title":"Nat Commun"},{"issue":"7","key":"9119_CR247","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ni.3489","volume":"17","author":"CS Klose","year":"2016","unstructured":"Klose CS, Artis D (2016) Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol 17(7):765\u2013774","journal-title":"Nat Immunol"},{"issue":"1","key":"9119_CR248","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/imr.12576","volume":"279","author":"L Pasman","year":"2017","unstructured":"Pasman L, Kasper DL (2017) Building conventions for unconventional lymphocytes. Immunol Rev 279(1):52\u201362","journal-title":"Immunol Rev"},{"issue":"3","key":"9119_CR249","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/imm.12862","volume":"153","author":"Y Simoni","year":"2018","unstructured":"Simoni Y, Newell EW (2018) Dissecting human ILC heterogeneity: more than just three subsets. Immunology 153(3):297\u2013303","journal-title":"Immunology"},{"issue":"8","key":"9119_CR250","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/eji.201747303","volume":"48","author":"M D\u00fcster","year":"2018","unstructured":"D\u00fcster M et al (2018) T cell-derived IFN\u2010\u03b3 downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus. Eur J Immunol 48(8):1364\u20131375","journal-title":"Eur J Immunol"},{"issue":"4","key":"9119_CR251","first-page":"676","volume":"37","author":"M Hou","year":"2019","unstructured":"Hou M, Liu S (2019) Innate lymphoid cells are increased in systemic lupus erythematosus. Clin Exp Rheumatol 37(4):676\u2013679","journal-title":"Clin Exp Rheumatol"},{"key":"9119_CR252","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clim.2019.03.008","volume":"202","author":"C Guo","year":"2019","unstructured":"Guo C et al (2019) Innate lymphoid cell disturbance with increase in ILC1 in systemic lupus erythematosus. Clin Immunol 202:49\u201358","journal-title":"Clin Immunol"},{"issue":"6","key":"9119_CR253","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1289\/ehp.11092","volume":"116","author":"GS Cooper","year":"2008","unstructured":"Cooper GS et al (2008) Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease. Environ Health Perspect 116(6):695\u2013702","journal-title":"Environ Health Perspect"},{"issue":"2","key":"9119_CR254","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaci.2022.09.022","volume":"151","author":"EM Mace","year":"2023","unstructured":"Mace EM (2023) Human natural killer cells: form, function, and development. J Allergy Clin Immunol 151(2):371\u2013385","journal-title":"J Allergy Clin Immunol"},{"key":"9119_CR255","doi-asserted-by":"crossref","unstructured":"Thangjam N et al (2023) Natural killer cell count in systemic lupus erythematosus patients: a flow cytometry-based study. Cureus 15(10)","DOI":"10.7759\/cureus.46885"},{"key":"9119_CR256","doi-asserted-by":"crossref","unstructured":"Liu M, Liang S, Zhang C (2021) NK cells in autoimmune diseases: protective or pathogenic? Front Immunol 12:624687","DOI":"10.3389\/fimmu.2021.624687"},{"issue":"9","key":"9119_CR257","first-page":"1768","volume":"41","author":"H Li","year":"2023","unstructured":"Li H et al (2023) CD56brightCD16-to CD57\u2009+\u2009CD56dimCD16\u2009+\u2009NK cell ratio discriminates disease activity and renal involvement in patients with systemic lupus erythematosus. Clin Exp Rheumatol 41(9):1768\u20131776","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"9119_CR258","doi-asserted-by":"publisher","first-page":"e0312141","DOI":"10.1371\/journal.pone.0312141","volume":"19","author":"A De la Cruz","year":"2024","unstructured":"De la Cruz A et al (2024) Immune complex deposition promotes NK cell accumulation in the kidney. PLoS ONE 19(11):e0312141","journal-title":"PLoS ONE"},{"issue":"3","key":"9119_CR259","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1189\/jlb.4A0714-326R","volume":"97","author":"R Spada","year":"2015","unstructured":"Spada R et al (2015) NKG2D ligand overexpression in lupus nephritis correlates with increased NK cell activity and differentiation in kidneys but not in the periphery. J Leucocyte Biology 97(3):583\u2013598","journal-title":"J Leucocyte Biology"},{"issue":"8","key":"9119_CR260","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3390\/cancers16081600","volume":"16","author":"M Zannikou","year":"2024","unstructured":"Zannikou M, Fish EN, Platanias LC (2024) Signaling by type I interferons in immune cells: disease consequences. Cancers 16(8):1600","journal-title":"Cancers"},{"issue":"1","key":"9119_CR261","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J et al (2020) Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 79(1):141\u2013149","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"9119_CR262","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.jaip.2022.04.036","volume":"10","author":"NR Pollock","year":"2022","unstructured":"Pollock NR, Harrison GF, Norman PJ (2022) Immunogenomics of killer cell immunoglobulin-like receptor (KIR) and HLA class I: coevolution and consequences for human health. J Allergy Clin Immunology: Pract 10(7):1763\u20131775","journal-title":"J Allergy Clin Immunology: Pract"},{"issue":"Suppl 2","key":"9119_CR263","doi-asserted-by":"publisher","first-page":"354","DOI":"10.31138\/mjr.010324.iis","volume":"35","author":"D Deligeorgakis","year":"2024","unstructured":"Deligeorgakis D, Skouvaklidou E, Adamichou C (2024) Interferon inhibition in SLE: from bench to bedside. Mediterr J Rheumatol 35(Suppl 2):354","journal-title":"Mediterr J Rheumatol"},{"issue":"2","key":"9119_CR264","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1365-2249.2010.04176.x","volume":"161","author":"P Lenert","year":"2010","unstructured":"Lenert P (2010) Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA-and\/or RNA-like analogues for treating lupus. Clin Exp Immunol 161(2):208\u2013222","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"9119_CR265","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2015.08.009","volume":"15","author":"MJ Jim\u00e9nez-Dalmaroni","year":"2016","unstructured":"Jim\u00e9nez-Dalmaroni MJ, Gerswhin ME, Adamopoulos IE (2016) The critical role of toll-like receptors\u2014from microbial recognition to autoimmunity: a comprehensive review. Autoimmun Rev 15(1):1\u20138","journal-title":"Autoimmun Rev"},{"issue":"5","key":"9119_CR266","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/08830185.2017.1365146","volume":"36","author":"K \u00c1lvarez","year":"2017","unstructured":"\u00c1lvarez K, Vasquez G (2017) Damage-associated molecular patterns and their role as initiators of inflammatory and auto-immune signals in systemic lupus erythematosus. Int Rev Immunol 36(5):259\u2013270","journal-title":"Int Rev Immunol"},{"key":"9119_CR267","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s10875-013-9887-0","volume":"33","author":"SK Chauhan","year":"2013","unstructured":"Chauhan SK et al (2013) Distinct autoantibody profiles in systemic lupus erythematosus patients are selectively associated with TLR7 and TLR9 upregulation. J Clin Immunol 33:954\u2013964","journal-title":"J Clin Immunol"},{"key":"9119_CR268","doi-asserted-by":"publisher","first-page":"1093208","DOI":"10.3389\/fimmu.2023.1093208","volume":"14","author":"L Wen","year":"2023","unstructured":"Wen L et al (2023) Toll-like receptors 7 and 9 regulate the proliferation and differentiation of B cells in systemic lupus erythematosus. Front Immunol 14:1093208","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR269","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/art.21553","volume":"54","author":"X Wu","year":"2006","unstructured":"Wu X, Peng SL (2006) Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheumatism: Official J Am Coll Rheumatol 54(1):336\u2013342","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"4","key":"9119_CR270","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaut.2009.11.001","volume":"34","author":"M-L Santiago-Raber","year":"2010","unstructured":"Santiago-Raber M-L et al (2010) Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. J Autoimmun 34(4):339\u2013348","journal-title":"J Autoimmun"},{"key":"9119_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11680","author":"MM Azab","year":"2022","unstructured":"Azab MM et al (2022) Association of TLR7 and TLR9 genes polymorphisms in Egyptian patients with systemic lupus erythematosus. Heliyon 8(11):e11680.\u00a0https:\/\/doi.org\/10.1016\/j.heliyon.2022.e11680","journal-title":"Heliyon"},{"key":"9119_CR272","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-017-1441-7","volume":"19","author":"G Murayama","year":"2017","unstructured":"Murayama G et al (2017) Enhanced IFN-\u03b1 production is associated with increased TLR7 retention in the lysosomes of palasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Therapy 19:1\u201311","journal-title":"Arthritis Res Therapy"},{"key":"9119_CR273","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3389\/fimmu.2018.01957","volume":"9","author":"K Sakata","year":"2018","unstructured":"Sakata K et al (2018) Up-regulation of TLR7-mediated IFN-\u03b1 production by plasmacytoid dendritic cells in patients with systemic lupus erythematosus. Front Immunol 9:1957","journal-title":"Front Immunol"},{"issue":"6","key":"9119_CR274","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.cytogfr.2014.07.019","volume":"25","author":"S Smith","year":"2014","unstructured":"Smith S, Jefferies C (2014) Role of DNA\/RNA sensors and contribution to autoimmunity. Cytokine Growth Factor Rev 25(6):745\u2013757","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"9119_CR275","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/art.40452","volume":"70","author":"KB Elkon","year":"2018","unstructured":"Elkon KB (2018) Cell death, nucleic acids, and immunity: inflammation beyond the grave. Arthritis Rheumatol 70(6):805\u2013816","journal-title":"Arthritis Rheumatol"},{"issue":"6121","key":"9119_CR276","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun L et al (2013) Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339(6121):786\u2013791","journal-title":"Science"},{"key":"9119_CR277","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2019.104094","volume":"77","author":"R Zhou","year":"2020","unstructured":"Zhou R et al (2020) The triggers of the cGAS-STING pathway and the connection with inflammatory and autoimmune diseases. Infect Genet Evol 77:104094","journal-title":"Infect Genet Evol"},{"key":"9119_CR278","doi-asserted-by":"publisher","first-page":"112114","DOI":"10.1016\/j.intimp.2024.112114","volume":"133","author":"X Gu","year":"2024","unstructured":"Gu X et al (2024) Therapeutic landscape in systemic lupus erythematosus: MtDNA activation of the cGAS-STING pathway. Int Immunopharmacol 133:112114","journal-title":"Int Immunopharmacol"},{"key":"9119_CR279","doi-asserted-by":"publisher","first-page":"905109","DOI":"10.3389\/fimmu.2022.905109","volume":"13","author":"H Wobma","year":"2022","unstructured":"Wobma H et al (2022) Dysregulation of the cGAS-STING pathway in Monogenic autoinflammation and lupus. Front Immunol 13:905109","journal-title":"Front Immunol"},{"issue":"9","key":"9119_CR280","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout A et al (2021) The cGAS\u2013STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol 21(9):548\u2013569","journal-title":"Nat Rev Immunol"},{"key":"9119_CR281","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.3389\/fimmu.2019.01636","volume":"10","author":"C G\u00fcnther","year":"2019","unstructured":"G\u00fcnther C (2019) Nucleic acid immunity in the pathogenesis of cutaneous lupus erythematosus. Front Immunol 10:1636","journal-title":"Front Immunol"},{"issue":"8","key":"9119_CR282","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","volume":"22","author":"YJ Crow","year":"2022","unstructured":"Crow YJ, Stetson DB (2022) The type I interferonopathies: 10 years on. Nat Rev Immunol 22(8):471\u2013483","journal-title":"Nat Rev Immunol"},{"issue":"6252","key":"9119_CR283","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1126\/science.aac7049","volume":"349","author":"BJ Liddicoat","year":"2015","unstructured":"Liddicoat BJ et al (2015) RNA editing by ADAR1 prevents MDA5 sensing of endogenous DsRNA as nonself. Science 349(6252):1115\u20131120","journal-title":"Science"},{"issue":"5","key":"9119_CR284","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ng.2933","volume":"46","author":"GI Rice","year":"2014","unstructured":"Rice GI et al (2014) Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet 46(5):503\u2013509","journal-title":"Nat Genet"},{"issue":"4","key":"9119_CR285","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/humu.23975","volume":"41","author":"GI Rice","year":"2020","unstructured":"Rice GI et al (2020) Genetic and phenotypic spectrum associated with IFIH1 gain-of\u2010function. Hum Mutat 41(4):837\u2013849","journal-title":"Hum Mutat"},{"key":"9119_CR286","doi-asserted-by":"publisher","first-page":"660953","DOI":"10.3389\/fgene.2021.660953","volume":"12","author":"W Xiao","year":"2021","unstructured":"Xiao W et al (2021) Case report: aicardi-gouti\u00e8res syndrome and singleton-merten syndrome caused by a gain-of-function mutation in IFIH1. Front Genet 12:660953","journal-title":"Front Genet"},{"key":"9119_CR287","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3389\/fimmu.2019.02452","volume":"10","author":"W Sun","year":"2019","unstructured":"Sun W et al (2019) Antiviral adaptor MAVS promotes murine lupus with a B cell autonomous role. Front Immunol 10:2452","journal-title":"Front Immunol"},{"key":"9119_CR288","unstructured":"Lenert PS (2006) Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus, vol 8. Arthritis research & therapy, pp 1\u201311"},{"key":"9119_CR289","doi-asserted-by":"crossref","unstructured":"Talukdar A, Mukherjee A, Ganguly D (2020) Small Molecule Modulators of Endo-Lysosomal Toll-like Receptors.","DOI":"10.1039\/9781788016544-00339"},{"issue":"20","key":"9119_CR290","doi-asserted-by":"publisher","first-page":"10905","DOI":"10.3390\/ijms252010905","volume":"25","author":"E Moysidou","year":"2024","unstructured":"Moysidou E et al (2024) Lymphocytes change their phenotype and function in systemic lupus erythematosus and lupus nephritis. Int J Mol Sci 25(20):10905","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9119_CR291","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/antib5010002","volume":"5","author":"B Dema","year":"2016","unstructured":"Dema B, Charles N (2016) Autoantibodies in SLE: specificities, isotypes and receptors. Antibodies 5(1):2","journal-title":"Antibodies"},{"issue":"1","key":"9119_CR292","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/imr.12821","volume":"292","author":"E Meffre","year":"2019","unstructured":"Meffre E, O\u2019Connor KC (2019) Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev 292(1):90\u2013101","journal-title":"Immunol Rev"},{"key":"9119_CR293","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3433","volume":"13","author":"T D\u00f6rner","year":"2011","unstructured":"D\u00f6rner T, Giesecke C, Lipsky PE (2011) Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 13:1\u201312","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"9119_CR294","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nri.2017.19","volume":"17","author":"D Nemazee","year":"2017","unstructured":"Nemazee D (2017) Mechanisms of central tolerance for B cells. Nat Rev Immunol 17(5):281\u2013294","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"9119_CR295","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","volume":"15","author":"SJ Rubin","year":"2019","unstructured":"Rubin SJ, Bloom MS, Robinson WH (2019) B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol 15(5):303\u2013315","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"9119_CR296","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.coi.2010.08.001","volume":"22","author":"A Basten","year":"2010","unstructured":"Basten A, Silveira PA (2010) B-cell tolerance: mechanisms and implications. Curr Opin Immunol 22(5):566\u2013574","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"9119_CR297","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41584-020-00544-4","volume":"17","author":"S Fillatreau","year":"2021","unstructured":"Fillatreau S, Manfroi B, D\u00f6rner T (2021) Toll-like receptor signalling in B cells during systemic lupus erythematosus. Nat Rev Rheumatol 17(2):98\u2013108","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"9119_CR298","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","volume":"165","author":"M Odendahl","year":"2000","unstructured":"Odendahl M et al (2000) Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165(10):5970\u20135979","journal-title":"J Immunol"},{"issue":"1","key":"9119_CR299","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/imr.12810","volume":"292","author":"SW Jackson","year":"2019","unstructured":"Jackson SW, Davidson A (2019) BAFF inhibition in SLE\u2014is tolerance restored? Immunol Rev 292(1):102\u2013119","journal-title":"Immunol Rev"},{"issue":"4","key":"9119_CR300","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1517\/14728222.2014.888415","volume":"18","author":"W Stohl","year":"2014","unstructured":"Stohl W (2014) Therapeutic targeting of the BAFF\/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 18(4):473\u2013489","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"9119_CR301","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1080\/08916934.2019.1700232","volume":"53","author":"Y Feng","year":"2020","unstructured":"Feng Y et al (2020) The pathological role of B cells in systemic lupus erythematosus: from basic research to clinical. Autoimmunity 53(2):56\u201364","journal-title":"Autoimmunity"},{"issue":"1","key":"9119_CR302","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1600-065X.2010.00938.x","volume":"237","author":"T Yoshida","year":"2010","unstructured":"Yoshida T et al (2010) Memory B and memory plasma cells. Immunol Rev 237(1):117\u2013139","journal-title":"Immunol Rev"},{"issue":"3","key":"9119_CR303","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","volume":"7","author":"F Hiepe","year":"2011","unstructured":"Hiepe F et al (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7(3):170\u2013178","journal-title":"Nat Rev Rheumatol"},{"key":"9119_CR304","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3389\/fimmu.2015.00425","volume":"6","author":"M Woods","year":"2015","unstructured":"Woods M, Zou Y-R, Davidson A (2015) Defects in germinal center selection in SLE. Front Immunol 6:425","journal-title":"Front Immunol"},{"issue":"2","key":"9119_CR305","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/08916934.2012.748751","volume":"46","author":"K Schroeder","year":"2013","unstructured":"Schroeder K, Herrmann M, Winkler TH (2013) The role of somatic hypermutation in the generation of pathogenic antibodies in SLE. Autoimmunity 46(2):121\u2013127","journal-title":"Autoimmunity"},{"key":"9119_CR306","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113869","author":"LT Krimpenfort","year":"2024","unstructured":"Krimpenfort LT, Degn SE, Heesters BA (2024) The follicular dendritic cell: at the germinal center of autoimmunity? Cell Rep 43(3):113869.\u00a0https:\/\/doi.org\/10.1016\/j.celrep.2024.113869","journal-title":"Cell Rep"},{"issue":"11","key":"9119_CR307","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ajpath.2020.07.015","volume":"190","author":"SE Dorraji","year":"2020","unstructured":"Dorraji SE et al (2020) Kidney tertiary lymphoid structures in lupus nephritis develop into large interconnected networks and resemble lymph nodes in gene signature. Am J Pathol 190(11):2203\u20132225","journal-title":"Am J Pathol"},{"issue":"1","key":"9119_CR308","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/08916934.2017.1280671","volume":"50","author":"PP Domeier","year":"2017","unstructured":"Domeier PP, Schell SL, Rahman ZS (2017) Spontaneous germinal centers and autoimmunity. Autoimmunity 50(1):4\u201318","journal-title":"Autoimmunity"},{"issue":"5","key":"9119_CR309","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.20151722","volume":"213","author":"PP Domeier","year":"2016","unstructured":"Domeier PP et al (2016) IFN-\u03b3 receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J Exp Med 213(5):715\u2013732","journal-title":"J Exp Med"},{"issue":"7","key":"9119_CR310","doi-asserted-by":"publisher","first-page":"e20231882","DOI":"10.1084\/jem.20231882","volume":"222","author":"AJ Fike","year":"2025","unstructured":"Fike AJ et al (2025) IRF7 controls spontaneous autoimmune germinal center and plasma cell checkpoints. J Exp Med 222(7):e20231882","journal-title":"J Exp Med"},{"issue":"9","key":"9119_CR311","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/1346-8138.14498","volume":"45","author":"T Kogame","year":"2018","unstructured":"Kogame T et al (2018) Analysis of possible structures of inducible skin-associated lymphoid tissue in lupus erythematosus profundus. J Dermatol 45(9):1117\u20131121","journal-title":"J Dermatol"},{"issue":"5","key":"9119_CR312","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.immuni.2012.10.010","volume":"37","author":"SK Lee","year":"2012","unstructured":"Lee SK et al (2012) Interferon-\u03b3 excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 37(5):880\u2013892","journal-title":"Immunity"},{"key":"9119_CR313","doi-asserted-by":"crossref","unstructured":"D\u00f6rner T, Lipsky PE (2024) The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol, : p. 1\u201313","DOI":"10.1038\/s41584-024-01179-5"},{"issue":"1","key":"9119_CR314","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/imr.13068","volume":"307","author":"S Phalke","year":"2022","unstructured":"Phalke S et al (2022) Molecular mechanisms controlling age-associated B cells in autoimmunity. Immunol Rev 307(1):79\u2013100","journal-title":"Immunol Rev"},{"issue":"1","key":"9119_CR315","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/imr.12741","volume":"288","author":"SA Jenks","year":"2019","unstructured":"Jenks SA et al (2019) Extrafollicular responses in humans and SLE. Immunol Rev 288(1):136\u2013148","journal-title":"Immunol Rev"},{"issue":"1","key":"9119_CR316","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1600-065X.2000.imr017515.x","volume":"175","author":"F Martin","year":"2000","unstructured":"Martin F, Kearney JF (2000) B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a natural immune memory. Immunol Rev 175(1):70\u201379","journal-title":"Immunol Rev"},{"issue":"1","key":"9119_CR317","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/joim.12529","volume":"281","author":"AA Bengtsson","year":"2017","unstructured":"Bengtsson AA, R\u00f6nnblom L (2017) Systemic lupus erythematosus: still a challenge for physicians. J Intern Med 281(1):52\u201364","journal-title":"J Intern Med"},{"key":"9119_CR318","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fimmu.2016.00198","volume":"7","author":"PI Lobo","year":"2016","unstructured":"Lobo PI (2016) Role of natural autoantibodies and natural IgM anti-leucocyte autoantibodies in health and disease. Front Immunol 7:198","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR319","first-page":"419029","volume":"2014","author":"A Mak","year":"2014","unstructured":"Mak A, Kow NY (2014) The pathology of T cells in systemic lupus erythematosus. J Immunol Res 2014(1):419029","journal-title":"J Immunol Res"},{"key":"9119_CR320","doi-asserted-by":"publisher","first-page":"988512","DOI":"10.3389\/fphar.2022.988512","volume":"13","author":"S Xiang","year":"2022","unstructured":"Xiang S et al (2022) Imbalance of helper T cell type 1, helper T cell type 2 and associated cytokines in patients with systemic lupus erythematosus: A meta-analysis. Front Pharmacol 13:988512","journal-title":"Front Pharmacol"},{"key":"9119_CR321","doi-asserted-by":"publisher","first-page":"816005","DOI":"10.3389\/fimmu.2022.816005","volume":"13","author":"Z Wu","year":"2022","unstructured":"Wu Z et al (2022) CD3\u2009+\u2009CD4-CD8-(Double-negative) T cells in inflammation, immune disorders and cancer. Front Immunol 13:816005","journal-title":"Front Immunol"},{"key":"9119_CR322","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3389\/fimmu.2018.01924","volume":"9","author":"DA Rao","year":"2018","unstructured":"Rao DA (2018) T cells that help B cells in chronically inflamed tissues. Front Immunol 9:1924","journal-title":"Front Immunol"},{"issue":"4","key":"9119_CR323","doi-asserted-by":"publisher","first-page":"646","DOI":"10.5603\/FHC.2011.0088","volume":"49","author":"W Kleczynska","year":"2011","unstructured":"Kleczynska W et al (2011) Imbalance between Th17 and regulatory T-cells in systemic lupus erythematosus. Folia Histochem Cytobiol 49(4):646\u2013653","journal-title":"Folia Histochem Cytobiol"},{"key":"9119_CR324","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v30.i1.10","author":"EJ Pone","year":"2010","unstructured":"Pone EJ et al (2010) Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses. Critical Reviews\u2122 in Immunology. https:\/\/doi.org\/10.1615\/CritRevImmunol.v30.i1.10","journal-title":"Critical Reviews\u2122 in Immunology"},{"issue":"6","key":"9119_CR325","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/sj.gene.6364408","volume":"8","author":"T Niewold","year":"2007","unstructured":"Niewold T et al (2007) High serum IFN-\u03b1 activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 8(6):492\u2013502","journal-title":"Genes Immun"},{"issue":"3","key":"9119_CR326","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/jcp.21815","volume":"220","author":"XF Qi","year":"2009","unstructured":"Qi XF et al (2009) Essential involvement of cross-talk between IFN\u2010\u03b3 and TNF\u2010\u03b1 in CXCL10 production in human THP\u20101 monocytes. J Cell Physiol 220(3):690\u2013697","journal-title":"J Cell Physiol"},{"issue":"9","key":"9119_CR327","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/icb.2017.53","volume":"95","author":"PM Guimar\u00e3es","year":"2017","unstructured":"Guimar\u00e3es PM et al (2017) Cytokines in systemic lupus erythematosus: Far beyond Th1\/Th2 dualism lupus: cytokine profiles. Immunol Cell Biol 95(9):824\u2013831","journal-title":"Immunol Cell Biol"},{"key":"9119_CR328","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02025","volume":"11","author":"W Wang","year":"2020","unstructured":"Wang W et al (2020) T helper (Th) cell profiles in pregnancy and recurrent pregnancy losses: Th1\/Th2\/Th9\/Th17\/Th22\/Tfh cells. Front Immunol 11:2025","journal-title":"Front Immunol"},{"issue":"2","key":"9119_CR329","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cyto.2015.05.007","volume":"76","author":"SMA Galil","year":"2015","unstructured":"Galil SMA, Ezzeldin N, El-Boshy ME (2015) The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine 76(2):280\u2013287","journal-title":"Cytokine"},{"issue":"5","key":"9119_CR330","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.4049\/jimmunol.0900385","volume":"183","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Kyttaris VC, Tsokos GC (2009) The role of IL-23\/IL-17 axis in lupus nephritis. J Immunol 183(5):3160\u20133169","journal-title":"J Immunol"},{"issue":"7","key":"9119_CR331","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1172\/JCI67390","volume":"123","author":"JS Knight","year":"2013","unstructured":"Knight JS et al (2013) Peptidylarginine deiminase Inhibition is Immunomodulatory and vasculoprotective in murine lupus. J Clin Investig 123(7):2981\u20132993","journal-title":"J Clin Investig"},{"issue":"1","key":"9119_CR332","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/s41467-020-16636-4","volume":"11","author":"H Li","year":"2020","unstructured":"Li H et al (2020) Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells. Nat Commun 11(1):2859","journal-title":"Nat Commun"},{"issue":"1","key":"9119_CR333","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","volume":"23","author":"KH Mills","year":"2023","unstructured":"Mills KH (2023) IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol 23(1):38\u201354","journal-title":"Nat Rev Immunol"},{"key":"9119_CR334","doi-asserted-by":"publisher","first-page":"624971","DOI":"10.3389\/fimmu.2020.624971","volume":"11","author":"T Koga","year":"2021","unstructured":"Koga T et al (2021) Current insights and future prospects for targeting IL-17 to treat patients with systemic lupus erythematosus. Front Immunol 11:624971","journal-title":"Front Immunol"},{"issue":"2","key":"9119_CR335","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1172\/JCI750","volume":"101","author":"D Balomenos","year":"1998","unstructured":"Balomenos D, Rumold R, Theofilopoulos AN (1998) Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 101(2):364\u2013371","journal-title":"J Clin Invest"},{"key":"9119_CR336","doi-asserted-by":"crossref","unstructured":"Cui X et al (2024) IL-12 family cytokines and autoimmune diseases: A potential therapeutic target? J Translational Autoimmun, : p. 100263","DOI":"10.1016\/j.jtauto.2024.100263"},{"issue":"8","key":"9119_CR337","doi-asserted-by":"publisher","first-page":"e156341","DOI":"10.1172\/jci.insight.156341","volume":"7","author":"GS Dunlap","year":"2022","unstructured":"Dunlap GS et al (2022) Single-cell transcriptomics reveals distinct effector profiles of infiltrating T cells in lupus skin and kidney. JCI Insight 7(8):e156341","journal-title":"JCI Insight"},{"issue":"1","key":"9119_CR338","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41392-024-02018-5","volume":"9","author":"Q Zhang","year":"2024","unstructured":"Zhang Q et al (2024) Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis. Signal Transduct Target Therapy 9(1):325","journal-title":"Signal Transduct Target Therapy"},{"issue":"8","key":"9119_CR339","doi-asserted-by":"publisher","first-page":"e1368","DOI":"10.1002\/iid3.1368","volume":"12","author":"S Wang","year":"2024","unstructured":"Wang S, Cui Y (2024) Clinical significance of serum CXCL9, CXCL10, and CXCL11 in patients with lupus nephritis. Immun Inflamm Dis 12(8):e1368","journal-title":"Immun Inflamm Dis"},{"issue":"15","key":"9119_CR340","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1042\/CS20220531","volume":"137","author":"Z Strizova","year":"2023","unstructured":"Strizova Z et al (2023) M1\/M2 macrophages and their overlaps\u2013myth or reality? Clin Sci 137(15):1067\u20131093","journal-title":"Clin Sci"},{"key":"9119_CR341","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro F et al (2018) Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol 9:847","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR342","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-025-00749-z","volume":"30","author":"Y Wu","year":"2025","unstructured":"Wu Y et al (2025) Immune cell aberrations in systemic lupus erythematosus: navigating the targeted therapies toward precision management. Cell Mol Biol Lett 30(1):73","journal-title":"Cell Mol Biol Lett"},{"issue":"4","key":"9119_CR343","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/antib9040069","volume":"9","author":"Y Lamri","year":"2020","unstructured":"Lamri Y, Charles N (2020) IgE in the pathogenesis of SLE: from pathogenic role to therapeutic target. Antibodies 9(4):69","journal-title":"Antibodies"},{"key":"9119_CR344","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3389\/fimmu.2018.02601","volume":"9","author":"C Afferni","year":"2018","unstructured":"Afferni C et al (2018) The pleiotropic Immunomodulatory functions of IL-33 and its implications in tumor immunity. Front Immunol 9:2601","journal-title":"Front Immunol"},{"issue":"12","key":"9119_CR345","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1111\/all.15843","volume":"78","author":"N Charles","year":"2023","unstructured":"Charles N et al (2023) Autoreactive ige: pathogenic role and therapeutic target in autoimmune diseases. Allergy 78(12):3118\u20133135","journal-title":"Allergy"},{"key":"9119_CR346","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004255","author":"M Himbert","year":"2024","unstructured":"Himbert M et al (2024) Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2024-004255","journal-title":"RMD Open"},{"issue":"1","key":"9119_CR347","doi-asserted-by":"publisher","first-page":"23475","DOI":"10.1038\/s41598-024-72564-z","volume":"14","author":"NP Duarte-Delgado","year":"2024","unstructured":"Duarte-Delgado NP et al (2024) Cytokine profiles and their correlation with clinical and blood parameters in rheumatoid arthritis and systemic lupus erythematosus. Sci Rep 14(1):23475","journal-title":"Sci Rep"},{"issue":"1","key":"9119_CR348","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s10238-021-00726-8","volume":"22","author":"Q Luo","year":"2022","unstructured":"Luo Q et al (2022) Increased TIM-3\u2009+\u2009PD-1\u2009+\u2009NK cells are associated with the disease activity and severity of systemic lupus erythematosus. Clin Experimental Med 22(1):47\u201356","journal-title":"Clin Experimental Med"},{"issue":"10","key":"9119_CR349","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.4049\/jimmunol.0802830","volume":"182","author":"DD Kish","year":"2009","unstructured":"Kish DD, Li X, Fairchild RL (2009) CD8 T cells producing IL-17 and IFN-\u03b3 initiate the innate immune response required for responses to antigen skin challenge. J Immunol 182(10):5949\u20135959","journal-title":"J Immunol"},{"issue":"11","key":"9119_CR350","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1172\/JCI120859","volume":"128","author":"JS Tilstra","year":"2018","unstructured":"Tilstra JS et al (2018) Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. J Clin Investig 128(11):4884\u20134897","journal-title":"J Clin Investig"},{"issue":"9","key":"9119_CR351","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41577-022-00693-5","volume":"22","author":"LS Walker","year":"2022","unstructured":"Walker LS (2022) The link between circulating follicular helper T cells and autoimmunity. Nat Rev Immunol 22(9):567\u2013575","journal-title":"Nat Rev Immunol"},{"key":"9119_CR352","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2392","volume":"10","author":"S Romagnani","year":"2008","unstructured":"Romagnani S (2008) Human Th17 cells. Arthritis Res Ther 10:1\u20138","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"9119_CR353","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1600-065X.2008.00631.x","volume":"223","author":"R Ettinger","year":"2008","unstructured":"Ettinger R, Kuchen S, Lipsky PE (2008) The role of IL-21 in regulating B\u2010cell function in health and disease. Immunol Rev 223(1):60\u201386","journal-title":"Immunol Rev"},{"key":"9119_CR354","doi-asserted-by":"crossref","unstructured":"Anand A (2003) Characterization of CD3\u2009+\u2009CD4-CD8-(double negative) T cells in patients with systemic lupus erythematosus (SLE). University of London, University College London (United Kingdom)","DOI":"10.1191\/0961203302lu235oa"},{"issue":"13","key":"9119_CR355","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.7150\/jca.39717","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y et al (2020) DNT cell-based immunotherapy: progress and applications. J Cancer 11(13):3717","journal-title":"J Cancer"},{"key":"9119_CR356","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102497","volume":"57","author":"B Kalyanaraman","year":"2022","unstructured":"Kalyanaraman B (2022) NAC, NAC, Knockin\u2019on Heaven\u2019s door: interpreting the mechanism of action of N-acetylcysteine in tumor and immune cells. Redox Biol 57:102497","journal-title":"Redox Biol"},{"issue":"1","key":"9119_CR357","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","volume":"29","author":"S Crotty","year":"2011","unstructured":"Crotty S (2011) Follicular helper CD4 T cells (Tfh). Annu Rev Immunol 29(1):621\u2013663","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"9119_CR358","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/eji.201545760","volume":"46","author":"P Blanco","year":"2016","unstructured":"Blanco P, Ueno H, Schmitt N (2016) T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis. Eur J Immunol 46(2):281\u2013290","journal-title":"Eur J Immunol"},{"issue":"9","key":"9119_CR359","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1177\/0961203314567750","volume":"24","author":"X Zhang","year":"2015","unstructured":"Zhang X et al (2015) Circulating CXCR5\u2009+\u2009CD4\u2009+\u2009helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production. Lupus 24(9):909\u2013917","journal-title":"Lupus"},{"key":"9119_CR360","doi-asserted-by":"publisher","first-page":"1204777","DOI":"10.3389\/fimmu.2023.1204777","volume":"14","author":"M Wang","year":"2023","unstructured":"Wang M et al (2023) Tertiary lymphoid structures as local perpetuators of organ-specific immune injury: implication for lupus nephritis. Front Immunol 14:1204777","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR361","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.25032","volume":"62","author":"N Simpson","year":"2010","unstructured":"Simpson N et al (2010) Expansion of Circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheumatism: Official J Am Coll Rheumatol 62(1):234\u2013244","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"key":"9119_CR362","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3389\/fimmu.2018.01536","volume":"9","author":"MM Xie","year":"2018","unstructured":"Xie MM, Dent AL (2018) Unexpected help: follicular regulatory T cells in the germinal center. Front Immunol 9:1536","journal-title":"Front Immunol"},{"key":"9119_CR363","doi-asserted-by":"publisher","first-page":"641013","DOI":"10.3389\/fimmu.2021.641013","volume":"12","author":"T Ding","year":"2021","unstructured":"Ding T et al (2021) Frontiers of autoantibodies in autoimmune disorders: crosstalk between Tfh\/Tfr and regulatory B cells. Front Immunol 12:641013","journal-title":"Front Immunol"},{"key":"9119_CR364","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-021-02535-6","volume":"23","author":"M Miao","year":"2021","unstructured":"Miao M et al (2021) Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. Arthritis Res Therapy 23:1\u20139","journal-title":"Arthritis Res Therapy"},{"issue":"1","key":"9119_CR365","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12016-025-09022-9","volume":"68","author":"AM Sivalingam","year":"2025","unstructured":"Sivalingam AM (2025) Emerging mechanisms and biomarkers associated with T-Cells and B-Cells in autoimmune disorders. Clin Rev Allergy Immunol 68(1):14","journal-title":"Clin Rev Allergy Immunol"},{"key":"9119_CR366","doi-asserted-by":"publisher","first-page":"750542","DOI":"10.3389\/fimmu.2021.750542","volume":"12","author":"P Grover","year":"2021","unstructured":"Grover P, Goel PN, Greene MI (2021) Regulatory T cells: regulation of identity and function. Front Immunol 12:750542","journal-title":"Front Immunol"},{"key":"9119_CR367","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2511","volume":"10","author":"DA Horwitz","year":"2008","unstructured":"Horwitz DA (2008) Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res Ther 10:1\u20139","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"9119_CR368","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/art.23268","volume":"58","author":"B Yan","year":"2008","unstructured":"Yan B et al (2008) Dysfunctional CD4+, CD25\u2009+\u2009regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-\u03b1\u2013producing antigen\u2010presenting cells. Arthritis Rheumatism: Official J Am Coll Rheumatol 58(3):801\u2013812","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"key":"9119_CR369","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s10753-016-0470-8","volume":"40","author":"J-H Tao","year":"2017","unstructured":"Tao J-H et al (2017) Foxp3, regulatory T cell, and autoimmune diseases. Inflammation 40:328\u2013339","journal-title":"Inflammation"},{"issue":"1","key":"9119_CR370","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/08916934.2019.1693545","volume":"53","author":"F Muhammad Yusoff","year":"2020","unstructured":"Muhammad Yusoff F, Wong KK, Mohd Redzwan N (2020) Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity 53(1):8\u201320","journal-title":"Autoimmunity"},{"issue":"3","key":"9119_CR371","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/eji.202048614","volume":"51","author":"V Niederlova","year":"2021","unstructured":"Niederlova V et al (2021) CD8\u2009+\u2009Tregs revisited: A heterogeneous population with different phenotypes and properties. Eur J Immunol 51(3):512\u2013530","journal-title":"Eur J Immunol"},{"key":"9119_CR372","doi-asserted-by":"publisher","first-page":"922958","DOI":"10.3389\/fimmu.2022.922958","volume":"13","author":"A Par\u00eds-Mu\u00f1oz","year":"2022","unstructured":"Par\u00eds-Mu\u00f1oz A, Aizpurua G, Barber DF (2022) Helios expression is downregulated on CD8\u2009+\u2009Treg in two mouse models of lupus during disease progression. Front Immunol 13:922958","journal-title":"Front Immunol"},{"issue":"8","key":"9119_CR373","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.autrev.2010.03.006","volume":"9","author":"RK Dinesh","year":"2010","unstructured":"Dinesh RK et al (2010) CD8\u2009+\u2009Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev 9(8):560\u2013568","journal-title":"Autoimmun Rev"},{"issue":"5","key":"9119_CR374","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B","volume":"44","author":"EJ Enyedy","year":"2001","unstructured":"Enyedy EJ et al (2001) Fc\u03f5 receptor type I \u03b3 chain replaces the deficient T cell receptor \u03b6 chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheumatism: Official J Am Coll Rheumatol 44(5):1114\u20131121","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"5","key":"9119_CR375","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1471-4906(03)00100-5","volume":"24","author":"GC Tsokos","year":"2003","unstructured":"Tsokos GC et al (2003) Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 24(5):259\u2013263","journal-title":"Trends Immunol"},{"issue":"8","key":"9119_CR376","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1021\/jm201271b","volume":"55","author":"R Singh","year":"2012","unstructured":"Singh R, Masuda ES, Payan DG (2012) Discovery and development of spleen tyrosine kinase (SYK) inhibitors. J Med Chem 55(8):3614\u20133643","journal-title":"J Med Chem"},{"key":"9119_CR377","doi-asserted-by":"publisher","first-page":"1230264","DOI":"10.3389\/fimmu.2023.1230264","volume":"14","author":"Y-G Tsai","year":"2023","unstructured":"Tsai Y-G et al (2023) Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus. Front Immunol 14:1230264","journal-title":"Front Immunol"},{"key":"9119_CR378","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3389\/fimmu.2018.01088","volume":"9","author":"T Katsuyama","year":"2018","unstructured":"Katsuyama T, Tsokos GC, Moulton VR (2018) Aberrant T cell signaling and subsets in systemic lupus erythematosus. Front Immunol 9:1088","journal-title":"Front Immunol"},{"key":"9119_CR379","doi-asserted-by":"crossref","unstructured":"He J et al (2020) Advances In systemic lupus erythematosus pathogenesis via mTOR signaling pathway. In Seminars In arthritis and rheumatism. Elsevier","DOI":"10.1016\/j.semarthrit.2019.09.022"},{"issue":"4","key":"9119_CR380","doi-asserted-by":"publisher","first-page":"e00010","DOI":"10.1097\/IN9.0000000000000010","volume":"4","author":"S Nasr","year":"2022","unstructured":"Nasr S, Perl A (2022) Principles behind SLE treatment with N-acetylcysteine. Immunometabolism 4(4):e00010","journal-title":"Immunometabolism"},{"issue":"2","key":"9119_CR381","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41584-019-0356-x","volume":"16","author":"A Sharabi","year":"2020","unstructured":"Sharabi A, Tsokos GC (2020) T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol 16(2):100\u2013112","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"9119_CR382","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1136\/ard-2022-222858","volume":"81","author":"RF van Vollenhoven","year":"2022","unstructured":"van Vollenhoven RF et al (2022) Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis 81(11):1556\u20131563","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"9119_CR383","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/art.40052","volume":"69","author":"VP Werth","year":"2017","unstructured":"Werth VP et al (2017) Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti\u2013interferon-\u03b3 antibody, in patients with discoid lupus erythematosus. Arthritis Rheumatol 69(5):1028\u20131034","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"9119_CR384","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","volume":"12","author":"SA Hasni","year":"2021","unstructured":"Hasni SA et al (2021) Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor Tofacitinib in systemic lupus erythematosus. Nat Commun 12(1):3391","journal-title":"Nat Commun"},{"issue":"10381","key":"9119_CR385","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401(10381):1011\u20131019","journal-title":"Lancet"},{"issue":"7","key":"9119_CR386","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/art.40828","volume":"71","author":"S Hasni","year":"2019","unstructured":"Hasni S et al (2019) Safety and tolerability of omalizumab: a randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus. Arthritis Rheumatol 71(7):1135\u20131140","journal-title":"Arthritis Rheumatol"},{"key":"9119_CR387","doi-asserted-by":"publisher","first-page":"2050313X2412840","DOI":"10.1177\/2050313X241284049","volume":"12","author":"M Waugh","year":"2024","unstructured":"Waugh M, Gavigan G (2024) Drug-induced subacute cutaneous lupus erythematosus secondary to dupilumab: A case report. SAGE Open Med Case Rep 12:2050313X241284049","journal-title":"SAGE Open Med Case Rep"},{"issue":"2","key":"9119_CR388","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/jaut.1996.0026","volume":"9","author":"S Sakaguchi","year":"1996","unstructured":"Sakaguchi S et al (1996) T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun 9(2):211\u2013220","journal-title":"J Autoimmun"},{"key":"9119_CR389","doi-asserted-by":"publisher","first-page":"657768","DOI":"10.3389\/fimmu.2021.657768","volume":"12","author":"CD Moorman","year":"2021","unstructured":"Moorman CD, Sohn SJ, Phee H (2021) Emerging therapeutics for immune tolerance: tolerogenic vaccines, T cell therapy, and IL-2 therapy. Front Immunol 12:657768","journal-title":"Front Immunol"},{"key":"9119_CR390","unstructured":"Panza F (2018) Specificity of marker autoantibodies in systemic lupus erythematosus: autoantibodies detected in SLE patients by a novel DNA\/histone H4 peptide complex"},{"issue":"4","key":"9119_CR391","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1084\/jem.177.4.1009","volume":"177","author":"SL Tiegs","year":"1993","unstructured":"Tiegs SL, Russell DM, Nemazee D (1993) Receptor editing in self-reactive bone marrow B cells. J Exp Med 177(4):1009\u20131020","journal-title":"J Exp Med"},{"key":"9119_CR392","unstructured":"Anolik JH (2007) B cell biology and dysfunction in SLE. Bulletin of the NYU hospital for joint diseases, 65(3)"},{"key":"9119_CR393","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110222","author":"S-NC Liossis","year":"2024","unstructured":"Liossis S-NC (2024) The abnormal signaling of the B cell receptor and coreceptors of lupus B cells. Clin Immunol. https:\/\/doi.org\/10.1016\/j.clim.2024.110222","journal-title":"Clin Immunol"},{"issue":"7","key":"9119_CR394","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nri.2017.24","volume":"17","author":"DJ Rawlings","year":"2017","unstructured":"Rawlings DJ et al (2017) Altered B cell signalling in autoimmunity. Nat Rev Immunol 17(7):421\u2013436","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"9119_CR395","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1074-7613(00)80669-X","volume":"9","author":"AP Prodeus","year":"1998","unstructured":"Prodeus AP et al (1998) A critical role for complement in maintenance of self-tolerance. Immunity 9(5):721\u2013731","journal-title":"Immunity"},{"issue":"3","key":"9119_CR396","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.it.2007.12.004","volume":"29","author":"M Zouali","year":"2008","unstructured":"Zouali M (2008) Receptor editing and receptor revision in rheumatic autoimmune diseases. Trends Immunol 29(3):103\u2013109","journal-title":"Trends Immunol"},{"issue":"4","key":"9119_CR397","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5415\/apallergy.0000000000000128","volume":"13","author":"X Meng","year":"2023","unstructured":"Meng X et al (2023) Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells. Asia Pac Allergy 13(4):175\u2013186","journal-title":"Asia Pac Allergy"},{"issue":"6","key":"9119_CR398","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","volume":"20","author":"M Thien","year":"2004","unstructured":"Thien M et al (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20(6):785\u2013798","journal-title":"Immunity"},{"issue":"6644","key":"9119_CR399","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1126\/science.adg6427","volume":"380","author":"CG Vinuesa","year":"2023","unstructured":"Vinuesa CG, Grenov A, Kassiotis G (2023) Innate virus-sensing pathways in B cell systemic autoimmunity. Science 380(6644):478\u2013484","journal-title":"Science"},{"issue":"1","key":"9119_CR400","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1600-065X.1998.tb01223.x","volume":"164","author":"MJ Mamula","year":"1998","unstructured":"Mamula MJ, Mamula MJ (1998) Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol Rev 164(1):231\u2013233","journal-title":"Immunol Rev"},{"key":"9119_CR401","unstructured":"Factor V (2024) autoimmune diseases Self-antigen Hormone receptors. Underwood\u2019s Pathology: a Clinical Approach-E-BOOK: Underwood\u2019s Pathology: a Clinical Approach-E-BOOK, : p. 151"},{"key":"9119_CR402","unstructured":"Carls\u00e9n M (2008) Aspects of T cell development contributing to autoimmunity."},{"issue":"2","key":"9119_CR403","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41577-023-00911-8","volume":"24","author":"KM Ashby","year":"2024","unstructured":"Ashby KM, Hogquist KA (2024) A guide to thymic selection of T cells. Nat Rev Immunol 24(2):103\u2013117","journal-title":"Nat Rev Immunol"},{"key":"9119_CR404","doi-asserted-by":"crossref","unstructured":"van Parijs L, Perez VL, Abbas AK (2007) Mechanisms of peripheral T cell tolerance. Novartis Foundation Symposium 215-Immunological Tolerance: Immunological Tolerance: Novartis Foundation Symposium 215. Wiley Online Library","DOI":"10.1002\/9780470515525.ch2"},{"issue":"7","key":"9119_CR405","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/art.23556","volume":"58","author":"RK Chowdary Venigalla","year":"2008","unstructured":"Chowdary Venigalla RK et al (2008) Reduced CD4+, CD25\u2009\u2013\u2009T cell sensitivity to the suppressive function of CD4+, CD25high, CD127\u2013\/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheumatism: Official J Am Coll Rheumatol 58(7):2120\u20132130","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"4","key":"9119_CR406","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41584-021-00741-9","volume":"18","author":"F Rosetti","year":"2022","unstructured":"Rosetti F et al (2022) Regulation of activated T cell survival in rheumatic autoimmune diseases. Nat Rev Rheumatol 18(4):232\u2013244","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"9119_CR407","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/ar625","volume":"5","author":"L R\u00f6nnblom","year":"2003","unstructured":"R\u00f6nnblom L, Alm GV (2003) Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 5(2):68","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"9119_CR408","doi-asserted-by":"publisher","first-page":"103016","DOI":"10.1016\/j.autrev.2021.103016","volume":"21","author":"E Chalayer","year":"2022","unstructured":"Chalayer E et al (2022) Fc receptors gone wrong: a comprehensive review of their roles in autoimmune and inflammatory diseases. Autoimmun Rev 21(3):103016","journal-title":"Autoimmun Rev"},{"issue":"8","key":"9119_CR409","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/rheumatology\/keh688","volume":"44","author":"G Riemekasten","year":"2005","unstructured":"Riemekasten G, Hahn B (2005) Key autoantigens in SLE. Rheumatology 44(8):975\u2013982","journal-title":"Rheumatology"},{"issue":"1","key":"9119_CR410","doi-asserted-by":"publisher","first-page":"432595","DOI":"10.1155\/2011\/432595","volume":"2011","author":"K Ohl","year":"2011","unstructured":"Ohl K, Tenbrock K (2011) Inflammatory cytokines in systemic lupus erythematosus. Biomed Res Int 2011(1):432595","journal-title":"Biomed Res Int"},{"issue":"3","key":"9119_CR411","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.4049\/jimmunol.1202388","volume":"190","author":"JM Kahlenberg","year":"2013","unstructured":"Kahlenberg JM et al (2013) Neutrophil extracellular trap\u2013associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 190(3):1217\u20131226","journal-title":"J Immunol"},{"key":"9119_CR412","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fimmu.2018.00427","volume":"9","author":"S Malkiel","year":"2018","unstructured":"Malkiel S et al (2018) Plasma cell differentiation pathways in systemic lupus erythematosus. Front Immunol 9:427","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR413","first-page":"347141","volume":"2012","author":"D-L Su","year":"2012","unstructured":"Su D-L et al (2012) Roles of pro-and anti\u2010inflammatory cytokines in the pathogenesis of SLE. Biomed Res Int 2012(1):347141","journal-title":"Biomed Res Int"},{"issue":"9","key":"9119_CR414","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.2215\/CJN.13791215","volume":"11","author":"AR Kitching","year":"2016","unstructured":"Kitching AR, Hutton HL (2016) The players: cells involved in glomerular disease. Clin J Am Soc Nephrol 11(9):1664\u20131674","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"9119_CR415","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-pharmtox-031320-111453","volume":"61","author":"KM Pollard","year":"2021","unstructured":"Pollard KM et al (2021) Mechanisms of environment-induced autoimmunity. Annu Rev Pharmacol Toxicol 61(1):135\u2013157","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"9119_CR416","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-065X.1999.tb01310.x","volume":"169","author":"OT Chan","year":"1999","unstructured":"Chan OT et al (1999) The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev 169(1):107\u2013121","journal-title":"Immunol Rev"},{"issue":"3","key":"9119_CR417","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/10408360500523837","volume":"43","author":"JG Routsias","year":"2006","unstructured":"Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG (2006) Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. Crit Rev Clin Lab Sci 43(3):203\u2013248","journal-title":"Crit Rev Clin Lab Sci"},{"key":"9119_CR418","unstructured":"T\u00f8mmer\u00e5s B (2008) Analysis of glomerular target structures for nephritic anti-dsDNA antibodies playing central roles in lupus nephritis. Universitetet i Troms&#248"},{"key":"9119_CR419","doi-asserted-by":"publisher","first-page":"1393814","DOI":"10.3389\/fimmu.2024.1393814","volume":"15","author":"OP Rekvig","year":"2024","unstructured":"Rekvig OP (2024) SLE: a cognitive step forward\u2014a synthesis of rethinking theories, causality, and ignored DNA structures. Front Immunol 15:1393814","journal-title":"Front Immunol"},{"issue":"12","key":"9119_CR420","doi-asserted-by":"publisher","first-page":"10066","DOI":"10.3390\/ijms241210066","volume":"24","author":"C-Y Tsai","year":"2023","unstructured":"Tsai C-Y et al (2023) Decipher the immunopathological mechanisms and set up potential therapeutic strategies for patients with lupus nephritis. Int J Mol Sci 24(12):10066","journal-title":"Int J Mol Sci"},{"issue":"4","key":"9119_CR421","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/jcm10040793","volume":"10","author":"DJ Caster","year":"2021","unstructured":"Caster DJ et al (2021) Patients with proliferative lupus nephritis have autoantibodies that React to Moesin and demonstrate increased glomerular Moesin expression. J Clin Med 10(4):793","journal-title":"J Clin Med"},{"issue":"20","key":"9119_CR422","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.108.771170","volume":"120","author":"TN Mayadas","year":"2009","unstructured":"Mayadas TN, Tsokos GC, Tsuboi N (2009) Mechanisms of immune complex\u2013mediated neutrophil recruitment and tissue injury. Circulation 120(20):2012\u20132024","journal-title":"Circulation"},{"issue":"8","key":"9119_CR423","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.humimm.2013.04.030","volume":"74","author":"RM Nisihara","year":"2013","unstructured":"Nisihara RM et al (2013) Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients. Hum Immunol 74(8):907\u2013910","journal-title":"Hum Immunol"},{"issue":"1","key":"9119_CR424","doi-asserted-by":"publisher","first-page":"20","DOI":"10.31138\/mjr.28.1.20","volume":"28","author":"N Galanopoulos","year":"2017","unstructured":"Galanopoulos N, Christoforidou A, Bezirgiannidou Z (2017) Lupus thrombocytopenia: pathogenesis and therapeutic implications. Mediterr J Rheumatol 28(1):20\u201326","journal-title":"Mediterr J Rheumatol"},{"key":"9119_CR425","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s10067-010-1479-2","volume":"29","author":"DS Domiciano","year":"2010","unstructured":"Domiciano DS, Shinjo SK (2010) Autoimmune hemolytic anemia in systemic lupus erythematosus: association with thrombocytopenia. Clin Rheumatol 29:1427\u20131431","journal-title":"Clin Rheumatol"},{"key":"9119_CR426","doi-asserted-by":"crossref","unstructured":"Mills KH, McGuirk P (2004) Antigen-specific regulatory T cells\u2014their induction and role in infection. Seminars in immunology. Elsevier","DOI":"10.1016\/j.smim.2003.12.006"},{"issue":"2","key":"9119_CR427","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nri3582","volume":"14","author":"M Guilliams","year":"2014","unstructured":"Guilliams M et al (2014) The function of Fc\u03b3 receptors in dendritic cells and macrophages. Nat Rev Immunol 14(2):94\u2013108","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"9119_CR428","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00109-016-1421-4","volume":"94","author":"M-L Eloranta","year":"2016","unstructured":"Eloranta M-L, R\u00f6nnblom L (2016) Cause and consequences of the activated type I interferon system in SLE. J Mol Med 94(10):1103\u20131110","journal-title":"J Mol Med"},{"issue":"9","key":"9119_CR429","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/art.1780390907","volume":"39","author":"K Isshi","year":"1996","unstructured":"Isshi K, Hirohata S (1996) Association of anti\u2013ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheumatism: Official J Am Coll Rheumatol 39(9):1483\u20131490","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"issue":"9","key":"9119_CR430","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ncprheum0895","volume":"4","author":"K Elkon","year":"2008","unstructured":"Elkon K, Casali P (2008) Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 4(9):491\u2013498","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"5","key":"9119_CR431","doi-asserted-by":"publisher","first-page":"10281","DOI":"10.3390\/ijms160510281","volume":"16","author":"SH Tay","year":"2015","unstructured":"Tay SH, Mak A (2015) Anti-NR2A\/B antibodies and other major molecular mechanisms in the pathogenesis of cognitive dysfunction in systemic lupus erythematosus. Int J Mol Sci 16(5):10281\u201310300","journal-title":"Int J Mol Sci"},{"issue":"3","key":"9119_CR432","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0039-6257(02)00289-8","volume":"47","author":"OM Durrani","year":"2002","unstructured":"Durrani OM, Gordon C, Murray PI (2002) Primary anti-phospholipid antibody syndrome (APS): current concepts. Surv Ophthalmol 47(3):215\u2013238","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"9119_CR433","doi-asserted-by":"publisher","first-page":"e13258","DOI":"10.1111\/aji.13258","volume":"85","author":"A Beltagy","year":"2021","unstructured":"Beltagy A et al (2021) Anti-phospholipid antibodies and reproductive failures. Am J Reprod Immunol 85(4):e13258","journal-title":"Am J Reprod Immunol"},{"issue":"4","key":"9119_CR434","doi-asserted-by":"publisher","first-page":"e1279","DOI":"10.1002\/cti2.1279","volume":"10","author":"M Trendelenburg","year":"2021","unstructured":"Trendelenburg M (2021) Autoantibodies against complement component C1q in systemic lupus erythematosus. Clin Translational Immunol 10(4):e1279","journal-title":"Clin Translational Immunol"},{"issue":"1","key":"9119_CR435","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33545\/26648482.2025.v7.i1a.4","volume":"7","author":"AMH Hadi","year":"2025","unstructured":"Hadi AMH, Abbas AA-H, Hassan JS (2025) Autoantibodies that associated with systemic lupus erythematosus patients: a review study. Int J Immunol 7(1):13\u201318","journal-title":"Int J Immunol"},{"issue":"1","key":"9119_CR436","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1146\/annurev.immunol.23.021704.115835","volume":"23","author":"R-F Guo","year":"2005","unstructured":"Guo R-F, Ward PA (2005) Role of C5a in inflammatory responses. Annu Rev Immunol 23(1):821\u2013852","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"9119_CR437","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3899\/jrheum.2022-1135","volume":"50","author":"F Crisafulli","year":"2023","unstructured":"Crisafulli F et al (2023) Variations of C3 and C4 before and during pregnancy in systemic lupus erythematosus: association with disease flares and obstetric outcomes. J Rhuematol 50(10):1296\u20131301","journal-title":"J Rhuematol"},{"issue":"3","key":"9119_CR438","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/ki.1988.186","volume":"34","author":"JW Fries","year":"1988","unstructured":"Fries JW, Mendrick DL, Rennke HG (1988) Determinants of immune complex-mediated glomerulonephritis. Kidney Int 34(3):333\u2013345","journal-title":"Kidney Int"},{"issue":"4","key":"9119_CR439","doi-asserted-by":"publisher","first-page":"101859","DOI":"10.1016\/j.berh.2023.101859","volume":"37","author":"A Shumilova","year":"2023","unstructured":"Shumilova A, Vital EM (2023) Musculoskeletal manifestations of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 37(4):101859","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"9119_CR440","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00415-011-6232-5","volume":"259","author":"MB Lauvsnes","year":"2012","unstructured":"Lauvsnes MB, Omdal R (2012) Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol 259:622\u2013629","journal-title":"J Neurol"},{"issue":"12","key":"9119_CR441","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/rheumatology\/kei142","volume":"44","author":"I Bruce","year":"2005","unstructured":"Bruce I (2005) Not only\u2026 but also\u2019: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 44(12):1492\u20131502","journal-title":"Rheumatology"},{"issue":"6","key":"9119_CR442","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736\u2013745","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9119_CR443","first-page":"5350960","volume":"2019","author":"D Aguirre-Valencia","year":"2019","unstructured":"Aguirre-Valencia D et al (2019) Therapeutic plasma exchange as management of complicated systemic lupus erythematosus and other autoimmune diseases. Autoimmune Dis 2019(1):5350960","journal-title":"Autoimmune Dis"},{"key":"9119_CR444","doi-asserted-by":"crossref","unstructured":"Kello N et al (2019) Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature. Seminars in arthritis and rheumatism. Elsevier","DOI":"10.1016\/j.semarthrit.2018.11.005"},{"issue":"3","key":"9119_CR445","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jaci.2020.06.036","volume":"146","author":"A Shock","year":"2020","unstructured":"Shock A, Humphreys D, Nimmerjahn F (2020) Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: lessons from therapeutic modalities targeting Fc\u03b3 receptors. J Allergy Clin Immunol 146(3):492\u2013500","journal-title":"J Allergy Clin Immunol"},{"key":"9119_CR446","volume-title":"The lupus book: A guide for patients and their families","author":"DJ Wallace","year":"2024","unstructured":"Wallace DJ (2024) The lupus book: A guide for patients and their families. Oxford University Press"},{"issue":"19","key":"9119_CR447","doi-asserted-by":"publisher","first-page":"14413","DOI":"10.3390\/ijms241914413","volume":"24","author":"P Richter","year":"2023","unstructured":"Richter P et al (2023) Cytokines in systemic lupus erythematosus\u2014focus on TNF-\u03b1 and IL-17. Int J Mol Sci 24(19):14413","journal-title":"Int J Mol Sci"},{"key":"9119_CR448","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2014.04.001","volume":"55","author":"Y Bao","year":"2014","unstructured":"Bao Y, Cao X (2014) The immune potential and immunopathology of cytokine-producing B cell subsets: a comprehensive review. J Autoimmun 55:10\u201323","journal-title":"J Autoimmun"},{"issue":"5","key":"9119_CR449","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.berh.2005.05.006","volume":"19","author":"JH Anolik","year":"2005","unstructured":"Anolik JH, Aringer M (2005) New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 19(5):859\u2013878","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"11","key":"9119_CR450","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrrheum.2013.147","volume":"9","author":"A Perl","year":"2013","unstructured":"Perl A (2013) Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol 9(11):674\u2013686","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"9119_CR451","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.autrev.2008.04.019","volume":"7","author":"BT Kurien","year":"2008","unstructured":"Kurien BT, Scofield RH (2008) Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 7(7):567\u2013573","journal-title":"Autoimmun Rev"},{"issue":"9","key":"9119_CR452","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nri.2016.78","volume":"16","author":"M Schlee","year":"2016","unstructured":"Schlee M, Hartmann G (2016) Discriminating self from non-self in nucleic acid sensing. Nat Rev Immunol 16(9):566\u2013580","journal-title":"Nat Rev Immunol"},{"key":"9119_CR453","doi-asserted-by":"publisher","first-page":"849086","DOI":"10.3389\/fmed.2022.849086","volume":"9","author":"L Moschetti","year":"2022","unstructured":"Moschetti L et al (2022) Endothelial dysfunction in systemic lupus erythematosus and systemic sclerosis: a common trigger for different microvascular diseases. Front Med 9:849086","journal-title":"Front Med"},{"issue":"5","key":"9119_CR454","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH (2017) Update on lupus nephritis. Clin J Am Soc Nephrol 12(5):825\u2013835","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"9119_CR455","doi-asserted-by":"publisher","first-page":"p19","DOI":"10.1159\/000101796","volume":"106","author":"BJ Ballermann","year":"2007","unstructured":"Ballermann BJ (2007) Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron Physiol 106(2):p19\u2013p25","journal-title":"Nephron Physiol"},{"issue":"9","key":"9119_CR456","doi-asserted-by":"publisher","first-page":"e1174","DOI":"10.1002\/cti2.1174","volume":"9","author":"W Qiao","year":"2020","unstructured":"Qiao W et al (2020) Lupus IgG deposition causes arthritis but inhibits bone destruction through competitive occupation of Fc\u03b3RI and reduced RANKL signalling. Clin Translational Immunol 9(9):e1174","journal-title":"Clin Translational Immunol"},{"key":"9119_CR457","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-020-00893-9","volume":"22","author":"Q Li","year":"2020","unstructured":"Li Q et al (2020) An update on the pathogenesis of skin damage in lupus. Curr Rheumatol Rep 22:1\u201315","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"9119_CR458","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.autrev.2018.12.004","volume":"18","author":"NP Duarte-Delgado","year":"2019","unstructured":"Duarte-Delgado NP, Vasquez G, Ortiz-Reyes BL (2019) Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus. Autoimmun Rev 18(4):426\u2013432","journal-title":"Autoimmun Rev"},{"key":"9119_CR459","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-9-13","volume":"9","author":"JM L\u00f3pez-Novoa","year":"2011","unstructured":"L\u00f3pez-Novoa JM et al (2011) Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. J Translational Med 9:1\u201326","journal-title":"J Translational Med"},{"issue":"8","key":"9119_CR460","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/01.CIR.93.8.1579","volume":"93","author":"M Hojnik","year":"1996","unstructured":"Hojnik M et al (1996) Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93(8):1579\u20131587","journal-title":"Circulation"},{"issue":"11","key":"9119_CR461","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3390\/biomedicines9111626","volume":"9","author":"P Leone","year":"2021","unstructured":"Leone P et al (2021) Lupus vasculitis: an overview. Biomedicines 9(11):1626","journal-title":"Biomedicines"},{"issue":"1","key":"9119_CR462","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0961203318817132","volume":"28","author":"K Tselios","year":"2019","unstructured":"Tselios K et al (2019) Disease course patterns in systemic lupus erythematosus. Lupus 28(1):114\u2013122","journal-title":"Lupus"},{"issue":"7","key":"9119_CR463","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1136\/annrheumdis-2020-217070","volume":"79","author":"F Saccon","year":"2020","unstructured":"Saccon F et al (2020) Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. Ann Rheum Dis 79(7):943\u2013950","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9119_CR464","first-page":"816729","volume":"2014","author":"ML Squance","year":"2014","unstructured":"Squance ML, Reeves GE, Bridgman H (2014) The lived experience of lupus flares: features, triggers, and management in an Australian female cohort. Int J Chronic Dis 2014(1):816729","journal-title":"Int J Chronic Dis"},{"issue":"3","key":"9119_CR465","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","volume":"81","author":"CC Almeida-Brasil","year":"2022","unstructured":"Almeida-Brasil CC et al (2022) Flares after hydroxychloroquine reduction or discontinuation: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis 81(3):370\u2013378","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"9119_CR466","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF Van Vollenhoven","year":"2014","unstructured":"Van Vollenhoven RF et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73(6):958\u2013967","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"9119_CR467","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/09114300.2018.1451593","volume":"41","author":"T Kondo","year":"2018","unstructured":"Kondo T, Amano K (2018) Era of steroid sparing in the management of immune-mediated inflammatory diseases. Immunol Med 41(1):6\u201311","journal-title":"Immunol Med"},{"issue":"2","key":"9119_CR468","doi-asserted-by":"publisher","first-page":"105523","DOI":"10.1016\/j.jbspin.2023.105523","volume":"90","author":"R Felten","year":"2023","unstructured":"Felten R et al (2023) New biologics and targeted therapies in systemic lupus: from new molecular targets to new indications. A systematic review. Joint Bone Spine 90(2):105523","journal-title":"Joint Bone Spine"},{"key":"9119_CR469","doi-asserted-by":"publisher","first-page":"106484","DOI":"10.1016\/j.phrs.2022.106484","volume":"186","author":"E Moslemi","year":"2022","unstructured":"Moslemi E et al (2022) Efficacy of vitamin D supplementation as an adjunct therapy for improving inflammatory and oxidative stress biomarkers: an umbrella meta-analysis. Pharmacol Res 186:106484","journal-title":"Pharmacol Res"},{"issue":"Supplement5","key":"9119_CR470","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/rheumatology\/keaa403","volume":"59","author":"G Ruiz-Irastorza","year":"2020","unstructured":"Ruiz-Irastorza G, Bertsias G (2020) Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology 59(Supplement5):v69\u2013v81","journal-title":"Rheumatology"},{"issue":"2","key":"9119_CR471","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jaci.2010.12.1087","volume":"127","author":"C Yildirim-Toruner","year":"2011","unstructured":"Yildirim-Toruner C, Diamond B (2011) Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 127(2):303\u2013312","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"9119_CR472","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","volume":"15","author":"J Wenzel","year":"2019","unstructured":"Wenzel J (2019) Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol 15(9):519\u2013532","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"9119_CR473","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F Mackay","year":"2009","unstructured":"Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9(7):491\u2013502","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"9119_CR474","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthr Rhuem 63(12):3918\u20133930","journal-title":"Arthr Rhuem"},{"issue":"1","key":"9119_CR475","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nbt.2076","volume":"30","author":"W Stohl","year":"2012","unstructured":"Stohl W, Hilbert DM (2012) The discovery and development of belimumab: the anti-BLyS\u2013lupus connection. Nat Biotechnol 30(1):69\u201377","journal-title":"Nat Biotechnol"},{"issue":"7","key":"9119_CR476","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl W et al (2012) Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthr Rhuem 64(7):2328\u20132337","journal-title":"Arthr Rhuem"},{"issue":"2","key":"9119_CR477","doi-asserted-by":"publisher","first-page":"102736","DOI":"10.1016\/j.autrev.2020.102736","volume":"20","author":"T M\u00f6ckel","year":"2021","unstructured":"M\u00f6ckel T et al (2021) B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev 20(2):102736","journal-title":"Autoimmun Rev"},{"key":"9119_CR478","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cytogfr.2021.11.004","volume":"64","author":"Y Zhang","year":"2022","unstructured":"Zhang Y et al (2022) B cell-activating factor and its targeted therapy in autoimmune diseases. Cytokine Growth Factor Rev 64:57\u201370","journal-title":"Cytokine Growth Factor Rev"},{"key":"9119_CR479","doi-asserted-by":"crossref","unstructured":"Oon S et al (2018) Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Seminars in arthritis and rheumatism. Elsevier","DOI":"10.1016\/j.semarthrit.2018.01.001"},{"key":"9119_CR480","doi-asserted-by":"crossref","unstructured":"Pl\u00fc\u00df M et al (2022) Belimumab for systemic lupus erythematosus\u2013Focus on lupus nephritis, vol 18. Human Vaccines & Immunotherapeutics, p 2072143. 5","DOI":"10.1080\/21645515.2022.2072143"},{"key":"9119_CR481","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fimmu.2020.00433","volume":"11","author":"C Kaegi","year":"2020","unstructured":"Kaegi C et al (2020) Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders. Front Immunol 11:433","journal-title":"Front Immunol"},{"key":"9119_CR482","doi-asserted-by":"publisher","first-page":"1472292","DOI":"10.3389\/fimmu.2024.1472292","volume":"15","author":"S Gao","year":"2025","unstructured":"Gao S et al (2025) Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in china: a systematic review and meta-analysis. Front Immunol 15:1472292","journal-title":"Front Immunol"},{"issue":"3","key":"9119_CR483","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1365-2796.2009.02207.x","volume":"267","author":"F Perosa","year":"2010","unstructured":"Perosa F et al (2010) CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J Intern Med 267(3):260\u2013277","journal-title":"J Intern Med"},{"issue":"2","key":"9119_CR484","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","volume":"21","author":"M Stockfelt","year":"2025","unstructured":"Stockfelt M, Teng YO, Vital EM (2025) Opportunities and limitations of B cell depletion approaches in SLE. Nat Rev Rheumatol 21(2):111\u2013126","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"9119_CR485","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6(5):859\u2013866","journal-title":"Am J Transplant"},{"issue":"2","key":"9119_CR486","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/1756-185X.12463","volume":"18","author":"CC Mok","year":"2015","unstructured":"Mok CC (2015) Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis 18(2):154\u2013163","journal-title":"Int J Rheum Dis"},{"issue":"11","key":"9119_CR487","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/art.22211","volume":"54","author":"G Cambridge","year":"2006","unstructured":"Cambridge G et al (2006) B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheumatism: Official J Am Coll Rheumatol 54(11):3612\u20133622","journal-title":"Arthritis Rheumatism: Official J Am Coll Rheumatol"},{"key":"9119_CR488","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","volume":"34","author":"K Tobinai","year":"2017","unstructured":"Tobinai K et al (2017) A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther 34:324\u2013356","journal-title":"Adv Ther"},{"issue":"1","key":"9119_CR489","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA et al (2022) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81(1):100\u2013107","journal-title":"Ann Rheum Dis"},{"key":"9119_CR490","doi-asserted-by":"crossref","unstructured":"Rovin B et al (2025) Results from the regency trial assessing efficacy and safety of obinutuzumab in active lupus nephritis. in The Journal of Rheumatology. The Journal of Rheumatology","DOI":"10.3899\/jrheum.2025-0390.O025"},{"issue":"7","key":"9119_CR491","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","volume":"15","author":"G Murphy","year":"2019","unstructured":"Murphy G, Isenberg DA (2019) New therapies for systemic lupus erythematosus\u2014past imperfect, future tense. Nat Rev Rheumatol 15(7):403\u2013412","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"9119_CR492","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S et al (2018) Association of Immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169\u2013e184169","journal-title":"JAMA Netw Open"},{"issue":"5","key":"9119_CR493","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","volume":"97","author":"E Crickx","year":"2020","unstructured":"Crickx E et al (2020) Anti-CD20\u2013mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney Int 97(5):885\u2013893","journal-title":"Kidney Int"},{"issue":"7","key":"9119_CR494","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander T et al (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74(7):1474\u20131478","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"9119_CR495","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0961203319896018","volume":"29","author":"A Segarra","year":"2020","unstructured":"Segarra A et al (2020) Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus 29(2):118\u2013125","journal-title":"Lupus"},{"issue":"8","key":"9119_CR496","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","volume":"29","author":"D Roccatello","year":"2023","unstructured":"Roccatello D et al (2023) Daratumumab monotherapy for refractory lupus nephritis. Nat Med 29(8):2041\u20132047","journal-title":"Nat Med"},{"issue":"1","key":"9119_CR497","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1600-065X.2009.00780.x","volume":"229","author":"PS Linsley","year":"2009","unstructured":"Linsley PS, Nadler SG (2009) The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 229(1):307\u2013321","journal-title":"Immunol Rev"},{"issue":"11","key":"9119_CR498","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38790","volume":"66","author":"AT Group","year":"2014","unstructured":"Group AT (2014) Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 66(11):3096\u20133104","journal-title":"Arthritis Rheumatol"},{"issue":"10381","key":"9119_CR499","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand EF et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401(10381):1001\u20131010","journal-title":"Lancet"},{"issue":"10","key":"9119_CR500","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/art.27601","volume":"62","author":"J Merrill","year":"2010","unstructured":"Merrill J et al (2010) The efficacy and safety of abatacept in patients with non\u2013life-threatening manifestations of systemic lupus erythematosus: results of a twelve\u2010month, multicenter, exploratory, phase IIb, randomized, double\u2010blind, placebo\u2010controlled trial. Arthritis Rheum 62(10):3077\u20133087","journal-title":"Arthritis Rheum"},{"issue":"12","key":"9119_CR501","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00296-023-05389-0","volume":"43","author":"E Calatayud","year":"2023","unstructured":"Calatayud E et al (2023) Experience with abatacept in refractory lupus nephritis. Rheumatol Int 43(12):2319\u20132326","journal-title":"Rheumatol Int"},{"issue":"1","key":"9119_CR502","first-page":"9943743","volume":"2021","author":"X Xia","year":"2021","unstructured":"Xia X, Yang J, Wang S (2021) Follicular regulatory T cells in systemic lupus erythematosus. J Immunol Res 2021(1):9943743","journal-title":"J Immunol Res"},{"issue":"1","key":"9119_CR503","first-page":"740619","volume":"2010","author":"LA Lieberman","year":"2010","unstructured":"Lieberman LA, Tsokos GC (2010) The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity. Biomed Res Int 2010(1):740619","journal-title":"Biomed Res Int"},{"issue":"3","key":"9119_CR504","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08830185.2023.2274574","volume":"43","author":"R Zhang","year":"2024","unstructured":"Zhang R et al (2024) Low-dose IL-2 therapy in autoimmune diseases: an update review. Int Rev Immunol 43(3):113\u2013137","journal-title":"Int Rev Immunol"},{"key":"9119_CR505","doi-asserted-by":"crossref","unstructured":"Akkur MA et al (2025) Efficacy and safety of Low-Dose Interleukin-2 therapy in systemic lupus erythematosus: A systematic review. Cureus, 17(5)","DOI":"10.7759\/cureus.83323"},{"key":"9119_CR506","doi-asserted-by":"crossref","unstructured":"Feng R et al (2024) Predictive biomarkers for low-dose IL-2 therapy efficacy in systemic lupus erythematosus: a clinical analysis, vol 26. Arthritis Research & Therapy, pp 1\u201311. 1","DOI":"10.1186\/s13075-024-03388-5"},{"issue":"1","key":"9119_CR507","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/S2665-9913(19)30018-9","volume":"1","author":"JY Humrich","year":"2019","unstructured":"Humrich JY et al (2019) Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol 1(1):e44\u2013e54","journal-title":"Lancet Rheumatol"},{"key":"9119_CR508","doi-asserted-by":"publisher","first-page":"911151","DOI":"10.3389\/fimmu.2022.911151","volume":"13","author":"A Raugh","year":"2022","unstructured":"Raugh A, Allard D, Bettini M (2022) Nature vs. nurture: FOXP3, genetics, and tissue environment shape Treg function. Front Immunol 13:911151","journal-title":"Front Immunol"},{"issue":"11","key":"9119_CR509","doi-asserted-by":"publisher","first-page":"102668","DOI":"10.1016\/j.autrev.2020.102668","volume":"19","author":"M Ramanujam","year":"2020","unstructured":"Ramanujam M et al (2020) Phoenix from the flames: rediscovering the role of the CD40\u2013CD40L pathway in systemic lupus erythematosus and lupus nephritis. Autoimmun Rev 19(11):102668","journal-title":"Autoimmun Rev"},{"issue":"10","key":"9119_CR510","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/0961203315574558","volume":"24","author":"A Tocoian","year":"2015","unstructured":"Tocoian A et al (2015) First-in-human trial of the safety, pharmacokinetics and immunogenicity of a pegylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus 24(10):1045\u20131056","journal-title":"Lupus"},{"issue":"11","key":"9119_CR511","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie RA et al (2021) Phase 2, randomized, placebo-controlled trial of dapirolizumab Pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology 60(11):5397\u20135407","journal-title":"Rheumatology"},{"issue":"5566","key":"9119_CR512","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1126\/science.1070238","volume":"296","author":"S Mandala","year":"2002","unstructured":"Mandala S et al (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296(5566):346\u2013349","journal-title":"Science"},{"key":"9119_CR513","doi-asserted-by":"publisher","first-page":"924766","DOI":"10.3389\/fimmu.2022.924766","volume":"13","author":"W Qiu","year":"2022","unstructured":"Qiu W, Yu T, Deng G-M (2022) The role of organ-deposited IgG in the pathogenesis of multi-organ and tissue damage in systemic lupus erythematosus. Front Immunol 13:924766","journal-title":"Front Immunol"},{"key":"9119_CR514","doi-asserted-by":"publisher","first-page":"iii116","DOI":"10.1136\/annrheumdis-2012-202371","volume":"72","author":"DD Patel","year":"2013","unstructured":"Patel DD et al (2013) Effect of IL-17A Blockade with Secukinumab in autoimmune diseases. Ann Rheum Dis 72:iii116\u2013iii123","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"9119_CR515","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/09612033221095692","volume":"31","author":"C-Y Hsieh","year":"2022","unstructured":"Hsieh C-Y, Tsai T-F (2022) Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: a case report and review of literature. Lupus 31(7):891\u2013894","journal-title":"Lupus"},{"issue":"6","key":"9119_CR516","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/08916934.2015.1037441","volume":"48","author":"D Li","year":"2015","unstructured":"Li D et al (2015) Interleukin-17 in systemic lupus erythematosus: a comprehensive review. Autoimmunity 48(6):353\u2013361","journal-title":"Autoimmunity"},{"issue":"1","key":"9119_CR517","doi-asserted-by":"publisher","first-page":"e002864","DOI":"10.1136\/rmdopen-2022-002864","volume":"9","author":"J Rodr\u00edguez-Carrio","year":"2023","unstructured":"Rodr\u00edguez-Carrio J et al (2023) Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open 9(1):e002864","journal-title":"RMD Open"},{"issue":"4","key":"9119_CR518","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/rheumatology\/keac491","volume":"62","author":"IN Bruce","year":"2023","unstructured":"Bruce IN et al (2023) Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials. Rheumatology 62(4):1526\u20131534","journal-title":"Rheumatology"},{"issue":"2","key":"9119_CR519","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie R et al (2017) Anifrolumab, an anti\u2013interferon-\u03b1 receptor monoclonal antibody, in moderate\u2010to\u2010severe systemic lupus erythematosus. Arthritis Rheumatol 69(2):376\u2013386","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"9119_CR520","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA et al (2019) Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 1(4):e208\u2013e219","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"9119_CR521","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1177\/09612033211014267","volume":"30","author":"R Furie","year":"2021","unstructured":"Furie R et al (2021) Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 30(8):1254\u20131263","journal-title":"Lupus"},{"key":"9119_CR522","doi-asserted-by":"publisher","first-page":"1759720X2093605","DOI":"10.1177\/1759720X20936059","volume":"12","author":"F Sunzini","year":"2020","unstructured":"Sunzini F, McInnes I, Siebert S (2020) JAK inhibitors and infections risk: focus on herpes Zoster. Therapeutic Adv Musculoskelet Disease 12:1759720X20936059","journal-title":"Therapeutic Adv Musculoskelet Disease"},{"issue":"10143","key":"9119_CR523","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ et al (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392(10143):222\u2013231","journal-title":"Lancet"},{"issue":"1","key":"9119_CR524","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13075-022-02794-x","volume":"24","author":"T D\u00f6rner","year":"2022","unstructured":"D\u00f6rner T et al (2022) Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther 24(1):112","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"9119_CR525","doi-asserted-by":"publisher","first-page":"e0320179","DOI":"10.1371\/journal.pone.0320179","volume":"20","author":"J Yin","year":"2025","unstructured":"Yin J et al (2025) Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials. PLoS ONE 20(4):e0320179","journal-title":"PLoS ONE"},{"issue":"3","key":"9119_CR526","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3390\/ijms26030929","volume":"26","author":"K Saegusa","year":"2025","unstructured":"Saegusa K et al (2025) Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches. Int J Mol Sci 26(3):929","journal-title":"Int J Mol Sci"},{"issue":"8","key":"9119_CR527","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/13543784.2024.2376566","volume":"33","author":"C Cruciani","year":"2024","unstructured":"Cruciani C et al (2024) Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development. Expert Opin Investig Drugs 33(8):801\u2013814","journal-title":"Expert Opin Investig Drugs"},{"key":"9119_CR528","doi-asserted-by":"crossref","unstructured":"Oke V et al (2019) High levels of Circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus, vol 21. Arthritis research & therapy, pp 1\u201311","DOI":"10.1186\/s13075-019-1878-y"},{"issue":"8","key":"9119_CR529","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gut.2005.079434","volume":"55","author":"W Reinisch","year":"2006","unstructured":"Reinisch W et al (2006) A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon \u03b3 antibody, in patients with moderate to severe crohn\u2019s disease. Gut 55(8):1138\u20131144","journal-title":"Gut"},{"issue":"3","key":"9119_CR530","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/13543784.2025.2473060","volume":"34","author":"A Bhatt","year":"2025","unstructured":"Bhatt A et al (2025) A focused report on IFN-1 targeted therapies for lupus erythematosus. Expert Opin Investig Drugs 34(3):121\u2013129","journal-title":"Expert Opin Investig Drugs"},{"key":"9119_CR531","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","volume":"78","author":"M Ahlmann","year":"2016","unstructured":"Ahlmann M, Hempel G (2016) The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol 78:661\u2013671","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"9119_CR532","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1191\/0961203304lu1027oa","volume":"13","author":"D Jayne","year":"2004","unstructured":"Jayne D, Tyndall A (2004) Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 13(5):359\u2013365","journal-title":"Lupus"},{"key":"9119_CR533","doi-asserted-by":"publisher","first-page":"100241","DOI":"10.1016\/j.jtauto.2024.100241","volume":"8","author":"MZ Moghaddam","year":"2024","unstructured":"Moghaddam MZ, Mousavi MJ, Ghotloo S (2024) Stem cell-based therapy for systemic lupus erythematous. J Translational Autoimmun 8:100241","journal-title":"J Translational Autoimmun"},{"key":"9119_CR534","doi-asserted-by":"publisher","first-page":"1476859","DOI":"10.3389\/fimmu.2024.1476859","volume":"15","author":"J Zhou","year":"2024","unstructured":"Zhou J et al (2024) CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Front Immunol 15:1476859","journal-title":"Front Immunol"},{"issue":"9","key":"9119_CR535","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett G et al (2024) Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat Rev Rheumatol 20(9):531\u2013544","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"9119_CR536","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132","journal-title":"Nat Med"},{"issue":"6","key":"9119_CR537","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jaci.2022.08.003","volume":"150","author":"M Doglio","year":"2022","unstructured":"Doglio M et al (2022) New insights in systemic lupus erythematosus: from regulatory T cells to CAR-T-cell strategies. J Allergy Clin Immunol 150(6):1289\u20131301","journal-title":"J Allergy Clin Immunol"},{"key":"9119_CR538","unstructured":"Yu K et al (2024) Allogenic CD19 CAR NK cells therapy in re\u2013fractory systemic lupus erythematosus: an open\u2013label, single arm, prospective and interventional clinical trial. ACR Convergence, : p. 14\u201319"},{"key":"9119_CR539","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ard.2025.05.396","volume":"84","author":"J Gao","year":"2025","unstructured":"Gao J et al (2025) LB0009 allogenic CD19 CAR NK cell therapy in refractory systemic lupus erythematosus-a case series study. Ann Rheum Dis 84:321","journal-title":"Ann Rheum Dis"},{"key":"9119_CR540","doi-asserted-by":"publisher","first-page":"1461102","DOI":"10.3389\/fimmu.2024.1461102","volume":"15","author":"J Yu","year":"2024","unstructured":"Yu J et al (2024) CAR immunotherapy in autoimmune diseases: promises and challenges. Front Immunol 15:1461102","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR541","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","volume":"14","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV et al (2025) The clinical landscape of CAR NK cells. Experimental Hematol Oncol 14(1):46","journal-title":"Experimental Hematol Oncol"},{"key":"9119_CR542","doi-asserted-by":"publisher","first-page":"612402","DOI":"10.3389\/fimmu.2020.612402","volume":"11","author":"WM Zelek","year":"2020","unstructured":"Zelek WM, Morgan BP (2020) Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Front Immunol 11:612402","journal-title":"Front Immunol"},{"issue":"7","key":"9119_CR543","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DR Jayne","year":"2021","unstructured":"Jayne DR et al (2021) Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 384(7):599\u2013609","journal-title":"N Engl J Med"},{"issue":"1","key":"9119_CR544","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40265-021-01643-6","volume":"82","author":"A Lee","year":"2022","unstructured":"Lee A (2022) Avacopan: first approval. Drugs 82(1):79\u201385","journal-title":"Drugs"},{"key":"9119_CR545","doi-asserted-by":"publisher","first-page":"1015128","DOI":"10.3389\/fimmu.2022.1015128","volume":"13","author":"J Ye","year":"2022","unstructured":"Ye J et al (2022) Complement C1s as a diagnostic marker and therapeutic target: progress and propective. Front Immunol 13:1015128","journal-title":"Front Immunol"},{"key":"9119_CR546","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13583","author":"R Honda","year":"2021","unstructured":"Honda R, Nakamura K, Ito S (2021) Case of hereditary angioedema with lupus erythematosus tumidus-like eruption. Australas J Dermatol. https:\/\/doi.org\/10.1111\/ajd.13583","journal-title":"Australas J Dermatol"},{"issue":"8","key":"9119_CR547","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.autrev.2008.06.006","volume":"7","author":"CG Kallenberg","year":"2008","unstructured":"Kallenberg CG (2008) Anti-C1Q autoantibodies. Autoimmun Rev 7(8):612\u2013615","journal-title":"Autoimmun Rev"},{"issue":"2","key":"9119_CR548","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1074-7613(00)00027-3","volume":"13","author":"S Bolland","year":"2000","unstructured":"Bolland S, Ravetch JV (2000) Spontaneous autoimmune disease in Fc\u03b3RIIB-deficient mice results from strain-specific epistasis. Immunity 13(2):277\u2013285","journal-title":"Immunity"},{"issue":"7","key":"9119_CR549","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik M et al (2023) The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol 23(7):415\u2013432","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"9119_CR550","doi-asserted-by":"publisher","first-page":"100052","DOI":"10.1016\/j.bdcasr.2024.100052","volume":"2","author":"K Nagatani","year":"2024","unstructured":"Nagatani K, Hayashi M (2024) Long-term use of Efgartigimod Alfa in treating a young adult with childhood-onset systemic lupus erythematosus and generalized myasthenia Gravis. Brain Dev Case Rep 2(4):100052","journal-title":"Brain Dev Case Rep"},{"issue":"4\u20135","key":"9119_CR551","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/0961203314556138","volume":"24","author":"N Schall","year":"2015","unstructured":"Schall N, Muller S (2015) Resetting the autoreactive immune system with a therapeutic peptide in lupus. Lupus 24(4\u20135):412\u2013418","journal-title":"Lupus"},{"key":"9119_CR552","unstructured":"Dombi E (2019) and M. Radic, of lupus regulator peptide P140 on mitochondria autophagy and. Autophagy in Autoimmunity, p 1881101"},{"key":"9119_CR553","volume-title":"ARTHRITIS AND RHEUMATISM","author":"R Zimmer","year":"2012","unstructured":"Zimmer R, Wallace DJ, Muller S (2012) Randomized, double-blind, placebo-controlled studies of P140 peptide in mannitol (Lupuzor) and Trehalose (Forigerimod) in patients with SLE. ARTHRITIS AND RHEUMATISM. WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030\u2009\u2013\u20095774, NJ USA"},{"key":"9119_CR554","doi-asserted-by":"publisher","first-page":"654701","DOI":"10.3389\/fimmu.2021.654701","volume":"12","author":"S Robinson","year":"2021","unstructured":"Robinson S, Thomas R (2021) Potential for antigen-specific tolerizing immunotherapy in systematic lupus erythematosus. Front Immunol 12:654701","journal-title":"Front Immunol"},{"key":"9119_CR555","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3389\/fimmu.2019.01601","volume":"10","author":"C Soni","year":"2019","unstructured":"Soni C, Reizis B (2019) Self-DNA at the epicenter of SLE: Immunogenic forms, regulation, and effects. Front Immunol 10:1601","journal-title":"Front Immunol"},{"key":"9119_CR556","doi-asserted-by":"publisher","first-page":"681062","DOI":"10.3389\/fimmu.2021.681062","volume":"12","author":"DA Horwitz","year":"2021","unstructured":"Horwitz DA, Bickerton S, La A, Cava (2021) Strategies to use nanoparticles to generate CD4 and CD8 regulatory T cells for the treatment of SLE and other autoimmune diseases. Front Immunol 12:681062","journal-title":"Front Immunol"},{"key":"9119_CR557","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3389\/fimmu.2020.00674","volume":"11","author":"A Cauwels","year":"2020","unstructured":"Cauwels A, Tavernier J (2020) Tolerizing strategies for the treatment of autoimmune diseases: from ex vivo to in vivo strategies. Front Immunol 11:674","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR558","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","volume":"15","author":"M Gatto","year":"2019","unstructured":"Gatto M et al (2019) New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 15(1):30\u201348","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"9119_CR559","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imr.12815","volume":"292","author":"JA Hamilton","year":"2019","unstructured":"Hamilton JA, Hsu HC, Mountz JD (2019) Autoreactive B cells in SLE, villains or innocent bystanders? Immunol Rev 292(1):120\u2013138","journal-title":"Immunol Rev"},{"issue":"5","key":"9119_CR560","doi-asserted-by":"publisher","first-page":"01548","DOI":"10.1128\/mbio","volume":"5","author":"A Hevia","year":"2014","unstructured":"Hevia A et al (2014) Intestinal dysbiosis associated with systemic lupus erythematosus. MBio 5(5):01548\u201301514. https:\/\/doi.org\/10.1128\/mbio","journal-title":"MBio"},{"key":"9119_CR561","doi-asserted-by":"publisher","first-page":"799788","DOI":"10.3389\/fimmu.2021.799788","volume":"12","author":"Q Pan","year":"2021","unstructured":"Pan Q et al (2021) Gut microbiota dysbiosis in systemic lupus erythematosus: novel insights into mechanisms and promising therapeutic strategies. Front Immunol 12:799788","journal-title":"Front Immunol"},{"key":"9119_CR562","doi-asserted-by":"publisher","first-page":"102844","DOI":"10.1016\/j.jaut.2022.102844","volume":"130","author":"C Huang","year":"2022","unstructured":"Huang C et al (2022) Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: an EXPLORER trial. J Autoimmun 130:102844","journal-title":"J Autoimmun"},{"issue":"8","key":"9119_CR563","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41577-024-01014-8","volume":"24","author":"ER Mann","year":"2024","unstructured":"Mann ER, Lam YK, Uhlig HH (2024) Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol 24(8):577\u2013595","journal-title":"Nat Rev Immunol"},{"key":"9119_CR564","doi-asserted-by":"crossref","unstructured":"Thieblemont N et al (2016) Human neutrophils In auto-immunity. In Seminars In immunology. Elsevier","DOI":"10.1016\/j.smim.2016.03.004"},{"key":"9119_CR565","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12026-013-8422-y","volume":"56","author":"E Ballanti","year":"2013","unstructured":"Ballanti E et al (2013) Complement and autoimmunity. Immunol Res 56:477\u2013491","journal-title":"Immunol Res"},{"key":"9119_CR566","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/bs.ircmb.2018.09.001","volume":"344","author":"V Bordignon","year":"2019","unstructured":"Bordignon V et al (2019) Nucleic acid sensing perturbation: how aberrant recognition of self-nucleic acids May contribute to autoimmune and autoinflammatory diseases. Int Rev Cell Mol Biology 344:117\u2013137","journal-title":"Int Rev Cell Mol Biology"},{"key":"9119_CR567","doi-asserted-by":"crossref","unstructured":"Barnas JL, Meffre E, Anolik JH (2021) B-cell biology, tolerance, and autoantibodies, in Lahita\u2019s Systemic Lupus Erythematosus. Elsevier, pp 71\u201380","DOI":"10.1016\/B978-0-12-820583-9.00036-1"},{"key":"9119_CR568","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.3389\/fimmu.2018.01884","volume":"9","author":"L Qin","year":"2018","unstructured":"Qin L et al (2018) Insights into the molecular mechanisms of T follicular helper-mediated immunity and pathology. Front Immunol 9:1884","journal-title":"Front Immunol"},{"issue":"1","key":"9119_CR569","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.it.2004.11.007","volume":"26","author":"S Jancar","year":"2005","unstructured":"Jancar S, Crespo MS (2005) Immune complex-mediated tissue injury: a multistep paradigm. Trends Immunol 26(1):48\u201355","journal-title":"Trends Immunol"},{"key":"9119_CR570","doi-asserted-by":"crossref","unstructured":"Land WG (2023) Basic trajectories in autoimmunity. Damage-Associated molecular patterns in human diseases: volume 3: Antigen-Related disorders. Springer, pp 383\u2013456","DOI":"10.1007\/978-3-031-21776-0_6"},{"key":"9119_CR571","unstructured":"Galli G (2022) The role of O-GlcNAcylation in the pathophysiology of Systemic Lupus Erythematosus. Universit\u00e9 de Bordeaux; McGill university (Montr\u00e9al, Canada)"},{"key":"9119_CR572","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41232-016-0015-4","volume":"36","author":"S Nakayamada","year":"2016","unstructured":"Nakayamada S, Tanaka Y (2016) BAFF-and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm Regen 36:1\u20136","journal-title":"Inflamm Regen"},{"issue":"6","key":"9119_CR573","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41584-023-00948-y","volume":"19","author":"S Fasano","year":"2023","unstructured":"Fasano S et al (2023) Precision medicine in systemic lupus erythematosus. Nat Rev Rheumatol 19(6):331\u2013342","journal-title":"Nat Rev Rheumatol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09119-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09119-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09119-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:02:31Z","timestamp":1767013351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09119-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":573,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9119"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09119-1","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This review article synthesizes findings from previously published studies and did not involve new research with human participants or animals conducted by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable. This manuscript contains no personally identifiable data from any individual.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}